<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-146-184</article-id>
<article-id pub-id-type="doi">10.26800/LV-146-5-6-4</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Drugs and procedures</subject></subj-group>
</article-categories>
<title-group>
<article-title>Promjena paradigme u onkolo&#x0161;koj rehabilitaciji &#x2013; nova na&#x010D;ela kinezioterapije i primjena izvantjelesnoga udarnog vala</article-title>
<trans-title-group xml:lang="en">
<trans-title>Paradigm shift in cancer rehabilitation &#x2013; new principles in kinesiotherapy and extracorporeal shock-wave therapy</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7964-7673</contrib-id><name><surname>Marunica Kar&#x0161;aj</surname><given-names>Jelena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brni&#x0107;</surname><given-names>Vedran</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brni&#x0107;</surname><given-names>Senija</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>Klinika za reumatologiju, fizikalnu medicinu i rehabilitaciju, Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu, Klini&#x010D;ki bolni&#x010D;ki centar Sestre milosrdnice</institution>, <addr-line>Zagreb</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Jelena Marunica Kar&#x0161;aj, dr. med., <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0009-0007-7964-7673">https://orcid.org/0009-0007-7964-7673</ext-link>, Klinika za reumatologiju, fizikalnu medicinu i rehabilitaciju, Klini&#x010D;ki bolni&#x010D;ki centar Sestre milosrdnice, Vinogradska cesta 29, 10000 Zagreb, e-po&#x0161;ta: <email xlink:href="jelenamarunica@yahoo.com">jelenamarunica@yahoo.com</email></corresp>
<fn fn-type="con">
<p content-type="fn-title">DOPRINOS AUTORA</p>
<p>K<sc>oncepcija</sc> <sc>ili</sc> <sc>nacrt</sc> <sc>rada</sc>: JMK, VB, SB</p>
<p>P<sc>rikupljanje</sc>, <sc>analiza</sc> <sc>i</sc> <sc>interpretacija</sc> <sc>podataka</sc>: JMK</p>
<p>P<sc>isanje</sc> <sc>prve</sc> <sc>verzije</sc> <sc>rada</sc>: JMK, VB, SB</p>
<p>K<sc>riti&#x010D;ka</sc> <sc>revizija</sc>: JMK, VB, SB</p>
</fn>
</author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>07</month><year>2024</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>07</month><year>2024</year></pub-date>
<volume>146</volume>
<issue>5-6</issue>
<fpage>184</fpage>
<lpage>194</lpage>
<permissions>
<copyright-statement>Croatian Medical Association</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Onkolo&#x0161;ka rehabilitacija primarno je fokusirana na individualne funkcionalne deficite i njihov u&#x010D;inak na onesposobljenost i kvalitetu &#x017E;ivota povezanu sa zdravljem. Potrebno je &#x0161;to ranije integrirati onkolo&#x0161;ku rehabilitaciju u kontinuum skrbi o onkolo&#x0161;kim bolesnicima. Najvrjedniji dio onkolo&#x0161;ke rehabilitacije predstavlja individualna kinezioterapija, s ciljem pobolj&#x0161;anja funkcionalnog zdravlja bolesnika. Iz razumljivih razloga mnogi onkolo&#x0161;ki bolesnici su smanjenih tjelesnih mogu&#x0107;nosti, snage i izdr&#x017E;ljivosti. Prednosti kinezioterapije su prepoznate u smislu pobolj&#x0161;anja tjelesnih kapaciteta, mentalnog zdravlja i kvalitete u razli&#x010D;itim aspektima &#x017E;ivota. U nekim tipovima malignih bolesti kontinuirana bi kinezioterapija mogla utjecati na pre&#x017E;ivljavanje. Sve se &#x010D;e&#x0161;&#x0107;e daje prednost treningu visokog intenziteta nasuprot etabliranim kontinuiranim vje&#x017E;bama umjerenog intenziteta. Pokazalo se da je vrijeme provedeno u zoni maksimalnoga aerobnog napora, pove&#x0107;avaju&#x0107;i maksimalni aerobni kapacitet, superiorno u odnosu na standardne umjerene vje&#x017E;be ili bez vje&#x017E;bi. Osnovana je Me&#x0111;unarodna radna skupina za provo&#x0111;enje vje&#x017E;bi (skr. <italic>IBMEWG</italic>) u bolesnika s ko&#x0161;tanim metastazama, budu&#x0107;i da bi isti mogli imati koristi od vje&#x017E;banja. U cilju prevladavanja potencijalnih funkcionalnih deficita u nadolaze&#x0107;em razdoblju onkolo&#x0161;kog lije&#x010D;enja va&#x017E;no mjesto zauzima prehabilitacija. U Hrvatskoj jedinica za onkolo&#x0161;ku rehabilitaciju djeluje od 1979. godine. Unutar brojnih zdravstvenih institucija diljem svijeta implementiran je koncept pod nazivom Sveobuhvatni centar za rak (engl. <italic>Comprehension Cancer Center, CCC</italic>) koji u sebi integrira razli&#x010D;ite jedinice, platforme i skupine. U Austriji je primjerice Tim za rehabilitaciju onkolo&#x0161;kih bolesnika (engl. <italic>Tumor Board for Cancer Rehabilitation</italic>) integriran unutar CCC Platforme za upravljanje nuspojavama, potpornu skrb i rehabilitaciju (engl. <italic>CCC Platform for Side Effects-Management, Supportive Care &amp; Rehabilitation</italic>), kao klini&#x010D;ki relevantan pristup u svrhu podr&#x0161;ke u kreiranju rehabilitacijskih strategija kod onkolo&#x0161;kih bolesnika. Kao odgovor na potrebu za u&#x010D;inkovitim, brzim i neinvazivnim lije&#x010D;enjem muskuloskeletnih bolesti unazad nekoliko godina razvio se interes za terapijom izvantjelesnim udarnim valom u kontekstu onkolo&#x0161;ke rehabilitacije. Nedavno se promijenila tradicionalna paradigma u vezi klini&#x010D;kih indikacija i kontraindikacija za propisivanje lije&#x010D;enja udarnim valom u onkolo&#x0161;kih bolesnika.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Cancer rehabilitation is primarily focused on individual functional deficits and their impact on disability and health-related quality of life. It is necessary to integrate cancer rehabilitation into the care continuum for these patients as soon as possible. The crown of cancer rehabilitation is individual kinesiotherapy to improve the patient&#x2019;s functional health. For understandable reasons, many cancer patients have reduced physical capabilities, strength, and endurance. The advantages of kinesiotherapy are widely known for improving physical capacities, mental health, and quality in various aspects of life. In some types of malignant diseases, continuous kinesiotherapy might have a favorable effect on survival. Moreover, some cancer patients prefer high-intensity training over established continuous moderate-intensity exercises. Time spent in the zone of maximum aerobic exertion, increasing maximum aerobic capacity, was shown to be superior to standard moderate exercise or without exercise. An International Bone Metastasis Exercise Working Group (<italic>IBMEWG</italic>) has been established to conduct exercises in patients with bone metastases since they could benefit from exercise. In order to overcome potential functional deficits in the upcoming period of oncologic treatment prehabilitation takes an important place. In Croatia, the cancer rehabilitation unit has been operating since 1979. Within numerous health institutions worldwide, a concept Comprehension Cancer Center (CCC) has been implemented which integrates different platforms, units, and groups. For example in Austria, the Tumor Board for Cancer Rehabilitation has been integrated within the CCC Platform for Side Effects-Management, Supportive Care &amp; Rehabilitation as a clinically relevant approach to support the creation of cancer rehabilitation strategies. In response to the need for effective, rapid, and non-invasive treatment of musculoskeletal diseases an interest in extracorporeal shock wave therapy (ESWL) has developed in the context of cancer rehabilitation over the past few years. Recently, the traditional paradigm regarding clinical indications and contraindications for prescribing ESWL in cancer patients has changed.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori PRE&#x017D;IVJELI OD RAKA</kwd><kwd>TUMORI &#x2013; rehabilitacija</kwd><kwd>KINEZIOTERAPIJA &#x2013; metode</kwd><kwd>IZVANTJELESNA TERAPIJA UDARNIM VALOM</kwd><kwd>TJELESNA AKTIVNOST</kwd><kwd>TRENING VISOKOG INTENZITETA</kwd><kwd>REHABILITACIJA &#x2013; metode, tendencija</kwd><kwd>KVALITETA &#x017D;IVOTA</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>CANCER SURVIVORS</kwd><kwd>NEOPLASMS &#x2013; rehabilitation</kwd><kwd>EXERCISE THERAPY &#x2013; methods</kwd><kwd>EXTRACORPOREAL SHOCKWAVE THERAPY</kwd><kwd>EXERCISE</kwd><kwd>HIGH-INTENSITY INTERVAL TRAINING</kwd><kwd>REHABILITATION &#x2013; methods, trends</kwd><kwd>QUALITY OF LIFE</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Porast broja onkolo&#x0161;kih bolesnika, unaprje&#x0111;enje prognoza ishoda malignih bolesti, kao i utjecaj kompleksnoga onkolo&#x0161;kog lije&#x010D;enja i same bolesti na fizi&#x010D;ko i psihi&#x010D;ko zdravlje pojedinca otvara potrebu za onkolo&#x0161;kom rehabilitacijom. S vi&#x0161;e se aspekata mo&#x017E;e razmatrati problematika onkolo&#x0161;ke rehabilitacije, no prije svega je klju&#x010D;an stru&#x010D;ni pogled na problematiku jer bi to moglo poticajno utjecati na promjene u zdravstvenom sustavu kako bi onkolo&#x0161;ka rehabilitacija bila dostupnija svima potrebitima. Cilj ovog rada je na&#x010D;eti temu kompleksne onkolo&#x0161;ke rehabilitacije s obzirom na to da nije uvelike zastupljena u doma&#x0107;im indeksiranim &#x010D;asopisima. O&#x010D;ekujemo da bi publiciranje stru&#x010D;nih radova iz ove problematike moglo senzibilizirati cijenjene kolege razli&#x010D;itih temelja specijalnosti na promi&#x0161;ljanje o istoj i samim time produbiti razli&#x010D;ite aspekte rehabilitacije koordinirane od kompetentnih stru&#x010D;njaka, poput propisivanja &#x0161;ireg spektra fizikalno terapijskih procedura, ovisno o op&#x0107;em stanju bolesnika i stadiju bolesti. Neizostavna je i adekvatna nutritivna potpora, psihoterapija i unaprje&#x0111;ivanje integracije bolesnika u zajednicu, &#x0161;to nadilazi okvire ovoga stru&#x010D;nog rada. Dostupnost i sveobuhvatnost onkolo&#x0161;ke rehabilitacije trebale bi biti preduvjetima povoljnog utjecaja na kvalitetu &#x017E;ivota povezanu sa zdravljem kod na&#x0161;ih bolesnika.</p>
<sec sec-type="other1">
<title>Teret maligne bolesti</title>
<p>Unaprje&#x0111;enje prognoze ishoda malignih bolesti rezultiralo je sve ve&#x0107;om potrebom za rje&#x0161;avanjem jedinstvenih zdravstvenih problema s kojima se suo&#x010D;avaju onkolo&#x0161;ki bolesnici, a koji su posljedica kako same bolesti, tako i njezinog lije&#x010D;enja, kao i komorbiditeta. Primjerice simptom umora mo&#x017E;e perzistirati kod 25% onkolo&#x0161;kih bolesnika mnogo godina nakon zavr&#x0161;etka lije&#x010D;enja i pridonosi pote&#x0161;ko&#x0107;ama u svakodnevnim aktivnostima, slabijoj kvaliteti &#x017E;ivota povezanoj sa zdravljem i povratku na posao. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) Nadalje, rizik od razvoja kardiovaskularnih bolesti mo&#x017E;e biti pove&#x0107;an uslijed odre&#x0111;enih modaliteta onkolo&#x0161;kog lije&#x010D;enja, a smrtnost od kardiovaskularnih bolesti pojavljuje se kao predominantni uzrok smrti zajedno s recidivom same maligne bolesti. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Incidencija malignih bolesti povezana je sa starenjem, napose u populaciji starijih od 70 godina. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) Negativni sinergijski u&#x010D;inci onkolo&#x0161;kog lije&#x010D;enja, dobi i povezanih posljedica pove&#x0107;avaju sveukupni teret maligne bolesti. Retrospektivno gledano, klini&#x010D;ari su obi&#x010D;no onkolo&#x0161;kim bolesnicima savjetovali izbjegavanje tjelesnih aktivnosti, te da vi&#x0161;e vremena posvete odmoru. Me&#x0111;utim, istra&#x017E;ivanja utjecaja tjelesne aktivnosti iz 1990-ih i 2000-ih godina osporila su dotada&#x0161;nje uvrije&#x017E;eno stajali&#x0161;te. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Naime, rezultati istra&#x017E;ivanja potvrdili su hipoteze kako su evaluacija bazi&#x010D;nih tjelesnih mogu&#x0107;nosti i provo&#x0111;enje vje&#x017E;bi op&#x0107;enito sigurni za onkolo&#x0161;ke bolesnike. Dakle, vi&#x0161;e ne vrijedi paradigma da bi onkolo&#x0161;ki bolesnici trebali &#x201E;izbjegavati tjelesnu aktivnost&#x201C;. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) Na raspolaganju je dovoljno utemeljenih dokaza koji upu&#x0107;uju da specifi&#x010D;ni aerobni trening, trening uz otpor te kombinirani trening uz otpor i aerobni trening pridonose pobolj&#x0161;anju prosje&#x010D;nih zdravstvenih ishoda povezanih s malignom bole&#x0161;&#x0107;u, uklju&#x010D;uju&#x0107;i kvalitetu &#x017E;ivota povezanu sa zdravljem, simptome depresije, anksioznost, tjelesno funkcioniranje i umor. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>)</p>
</sec>
<sec sec-type="other2">
<title>Zna&#x010D;enje kinezioterapije unutar onkolo&#x0161;ke rehabilitacije</title>
<p>Zahvaljuju&#x0107;i uspje&#x0161;nijem onkolo&#x0161;kom lije&#x010D;enju stope pre&#x017E;ivljenja onkolo&#x0161;kih bolesnika se pove&#x0107;avaju. Kako dio onkolo&#x0161;kih bolesnika &#x017E;ivi dulje, &#x010D;esto se javljaju funkcionalni deficiti lokomotornog sustava koji naru&#x0161;avaju kvalitetu &#x017E;ivota povezanu sa zdravljem. Zbog toga je neophodno &#x0161;to ranije integrirati onkolo&#x0161;ku rehabilitaciju u kontinuum skrbi onkolo&#x0161;kih bolesnika. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Pobolj&#x0161;anje stope pre&#x017E;ivljenja je nedostatno ako se ne optimizira pobolj&#x0161;anje kvalitete &#x017E;ivota onkolo&#x0161;kih bolesnika, &#x0161;to je cilj stru&#x010D;nog tima u okviru ove specifi&#x010D;ne kazuistike. Stru&#x010D;ni tim &#x010D;ine zdravstveni djelatnici multidisciplinarnih i interdisciplinarnih kompetencija, koji unutar onkolo&#x0161;ke rehabilitacije definiraju i planiraju individualni rehabilitacijski koncept. Za postizanje sveobuhvatne rehabilitacije onkolo&#x0161;kih bolesnika neophodna je tijesna suradnja stru&#x010D;njaka razli&#x010D;itih temelja specijalnosti i pristupa. Individualna kinezioterapija zauzima sredi&#x0161;nje mjesto unutar onkolo&#x0161;ke rehabilitacije. Specijalist fizikalne medicine i rehabilitacije, osim razli&#x010D;itih fizikalnoterapijskih procedura propisuje i ortopedska pomagala kao &#x0161;to su hodalice, ortoze, invalidska kolica; za kupiranje boli propisuje farmakolo&#x0161;ku terapiju &#x2013; sve u svrhu pobolj&#x0161;anja funkcionalnog zdravlja bolesnika. Onkolo&#x0161;ki bolesnici ve&#x0107;inom su za vrijeme i nakon provedenog onkolo&#x0161;kog lije&#x010D;enja dekondicionirani i pate od poja&#x010D;anog umora, &#x0161;to smanjuje njihove tjelesne mogu&#x0107;nosti i shodno tomu naru&#x0161;ava njihove svakodnevne aktivnosti. Pove&#x0107;anje aerobnog kapaciteta kod onkolo&#x0161;kih bolesnika, zahvaljuju&#x0107;i provo&#x0111;enju kinezioterapije za vrijeme ili nakon onkolo&#x0161;kog lije&#x010D;enja, nije samo povezano sa smanjenjem sindroma kroni&#x010D;nog umora, ve&#x0107; i sa zna&#x010D;ajnim pobolj&#x0161;anjem razli&#x010D;itih aspekata kvalitete &#x017E;ivota i, &#x0161;tovi&#x0161;e, dokumentirano je kako bi u nekim vrstama malignih bolesti kontinuirana kinezioterapija mogla povoljno utjecati na pre&#x017E;ivljenje. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r9"><italic>9</italic></xref>)</p>
</sec>
<sec sec-type="other3">
<title>Organizacija onkolo&#x0161;ke rehabilitacije u Hrvatskoj i u svijetu</title>
<p>Slu&#x017E;ba onkolo&#x0161;ke rehabilitacije osnovana je 1979. godine u tada&#x0161;njem Institutu za tumore u Zagrebu. Dana&#x0161;nja ustrojbena jedinica za rehabilitaciju onkolo&#x0161;kih bolesnika nalazi se na istoj lokaciji unutar Klinike za tumore kao integralni dio kompleksnog lije&#x010D;enja onkolo&#x0161;kih bolesnika. Rehabilitacija se prote&#x017E;e kroz sve modalitete lije&#x010D;enja i oporavka te sve stadije bolesti. U klini&#x010D;koj praksi za sada jo&#x0161; nije etablirana preoperativna fizijatrijska funkcionalna procjena onkolo&#x0161;kog bolesnika. Rehabilitacija zapo&#x010D;inje unutar bolni&#x010D;kog lije&#x010D;enja i prema potrebi uklju&#x010D;uje i psihoterapijsku procjenu. Osim bolni&#x010D;ke postoperativne rehabilitacije, prema indikaciji onkolo&#x0161;kog fizijatra uz provo&#x0111;enje kinezioterapije pod stru&#x010D;nim nadzorom fizioterapeuta provodi se ambulantna fizikalna terapija za vrijeme ili nakon kemoterapije i radioterapije sukladno medicinskoj indikaciji. Nastavak lije&#x010D;enja se odvija ambulantno vezano za kazuistiku bolesti sustava za kretanje kao i posljedice onkolo&#x0161;kog lije&#x010D;enja, primjerice lije&#x010D;enje limfedema, kemoterapijom inducirane polineuropatije, osteoporoze i drugo. Onkolo&#x0161;ki fizijatar uz edukaciju bolesnika propisuje dominantno kinezioterapiju, a ostale fizikalnoterapijske procedure propisuju se ovisno o stadiju i pro&#x0161;irenosti onkolo&#x0161;ke bolesti te lokalizaciji tretiranog podru&#x010D;ja. S obzirom na to da predstavlja &#x010D;istu elektroanalgezijsku proceduru li&#x0161;enu dubinskog termoterapijskog u&#x010D;inka i hiperemije, naj&#x010D;e&#x0161;&#x0107;e se propisuje TENS (engl. <italic>transcutaneous electric nerve stimulation</italic>) iz domene elektroterapijskih procedura. Za lije&#x010D;enje bolne i upalne komponente unutar patologije lokomotornog sustava onkolo&#x0161;ki fizijatar propisuje farmakoterapiju respektiraju&#x0107;i komorbiditete. Sukladno funkcionalnim deficitima onkolo&#x0161;kih bolesnika u svakodnevnom klini&#x010D;kom radu propisuje ortopedska pomagala te propisuje provo&#x0111;enje fizikalne terapije u ku&#x0107;i uz stru&#x010D;ni nadzor fizioterapeuta za te&#x0161;ko pokretne i nepokretne bolesnike. Unutar brojnih zdravstvenih institucija diljem svijeta implementiran je koncept pod nazivom Sveobuhvatni centar za rak (engl. <italic>Comprehension Cancer Center</italic>, <italic>CCC</italic>) koji u sebi integrira razli&#x010D;ite jedinice, platforme i skupine. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Primjerice u Austriji jedinice CCC-a su podijeljene prema primarnom sijelu maligne bolesti, npr. jedinica za rak debelog crijeva, tumori organa za kretanje tipa sarkomi, rak dojke, tumori sredi&#x0161;njeg &#x017E;iv&#x010D;anog sustava, neuroendokrini tumori, tumori probavnog sustava, tumori mokra&#x0107;nog sustava i rak pankreasa. Platforme CCC obuhva&#x0107;aju platformu za probir, ciljano onkolo&#x0161;ko lije&#x010D;enje, molekularnu dijagnostiku tumora i intimno zdravlje onkolo&#x0161;kih bolesnika, ekstravazaciju citostatika te skrb vezanu za toksi&#x010D;nost i nuspojave onkolo&#x0161;kih lijekova. Skupine su organizirane u domenu tumorske genetike i epigenetike, prevencije malignih bolesti, toksikologije i nuspojave onkolo&#x0161;kih lijekova, tumorske imunologije, rezistencije na citotoksi&#x010D;ne lijekove, eksperimentalnog lije&#x010D;enja, mikrookru&#x017E;enja maligne bolesti, tumorske vaskularizacije i pro&#x0161;irenosti metastaza te razvoja dijagnosti&#x010D;ko-terapijskih procedura. Ovakav pristup je osim porasta kvalitete &#x017E;ivota bolesnika pokazao i pobolj&#x0161;anu adherenciju na onkolo&#x0161;ko lije&#x010D;enje. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>, <xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Potaknuto publikacijom japanskih autora o klini&#x010D;kim pitanjima unutar onkolo&#x0161;ke rehabilitacije bolesnika prvenstveno sa skeletnim metastazama osnovan je prvi multidisciplinarni tzv. odbor za tumore. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) Unutar medicinskog fakulteta u Be&#x010D;u 2010. godine uspostavljen je tzv. Tim za rehabilitaciju onkolo&#x0161;kih bolesnika (engl. <italic>Tumor Board for Cancer Rehabilitation</italic>) te je integriran 2015. godine u CCC Platformu za upravljanje nuspojavama, potpornu skrb i rehabilitaciju (engl. <italic>CCC Platform for Side effects-Management, Supportive Care &amp; Rehabilitation</italic>), kao klini&#x010D;ki relevantan pristup u svrhu podr&#x0161;ke u kreiranju rehabilitacijskih strategija kod onkolo&#x0161;kih bolesnika. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>, <xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Kompleksni su onkolo&#x0161;ki slu&#x010D;ajevi predmet rasprave izme&#x0111;u specijalista razli&#x010D;itih medicinskih specijalnosti uklju&#x010D;enih u odbor. Uz onkologe i radioterapeute, unutar odbora objedinjene su kompetencije razli&#x010D;itih profila stru&#x010D;njaka kao &#x0161;to su kirurzi, traumatolozi, ortopedi, radiolozi. Rad odbora koordiniran je od strane lije&#x010D;nika specijalista fizikalne i rehabilitacijske medicine s u&#x017E;om ekspertizom u podru&#x010D;ju onkolo&#x0161;ke rehabilitacije. Tako&#x0111;er suradnici kao &#x0161;to su fizioterapeuti, klini&#x010D;ki psiholozi i nutricionisti upotpunjuju multidisciplinarni i interdisciplinarni tim. Indikacijsko podru&#x010D;je odbora usmjereno je prema onim onkolo&#x0161;kim bolesnicima koji su smanjenog kapaciteta posebice snage i izdr&#x017E;ljivosti, bolesnici s prisutno&#x0161;&#x0107;u tumorskog procesa na mozgu, s metastatskim lezijama skeletnog sustava, sa zna&#x010D;ajnim kardiovaskularnim i pulmonalnim komorbiditetom, s poreme&#x0107;ajem metaboli&#x010D;kog sustava, s kemoterapijski induciranom polineuropatijom te kod razli&#x010D;itih nuspojava onkolo&#x0161;kog lije&#x010D;enja. Za kompleksne onkolo&#x0161;ke bolesnike s prate&#x0107;im individualnim funkcionalnim deficitima i komorbiditetima, nakon sastanka stru&#x010D;nog odbora, donosi se odluka o smjeru i sadr&#x017E;aju individualnoga rehabilitacijskog koncepta. Odluka mo&#x017E;e i&#x0107;i u smjeru kontraindikacije za zapo&#x010D;injanje procesa rehabilitacije uslijed razli&#x010D;itih ugro&#x017E;avaju&#x0107;ih bolesti i stanja, no u ve&#x0107;ini slu&#x010D;ajeva propisuje se individualni rehabilitacijski plan uz prethodnu potrebnu dijagnosti&#x010D;ku obradu. Naj&#x010D;e&#x0161;&#x0107;e je to propisivanje kinezioterapije pod stru&#x010D;nim nadzorom fizioterapeuta te prema medicinskoj indikaciji i lije&#x010D;enje izvantjelesnim udarnim valom ili druge fizikalnoterapijske procedure, adekvatna nutritivna potpora, prema potrebi farmakolo&#x0161;ko lije&#x010D;enje boli i periodi&#x010D;no za neke bolesnike neizostavna psiho-onkolo&#x0161;ka savjetovali&#x0161;ta. (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) Kao &#x0161;to je ve&#x0107; navedeno, kod mnogih onkolo&#x0161;kih bolesnika prisutan je osje&#x0107;aj op&#x0107;e slabosti, dekondicioniranosti i umora, &#x0161;to zna&#x010D;ajno umanjuje kvalitetu &#x017E;ivota u svim aspektima. Redovita i dosljedna tjelesna aktivnost potencijalno umanjuje nuspojave onkolo&#x0161;kog lije&#x010D;enja pobolj&#x0161;avaju&#x0107;i izdr&#x017E;ljivost i mi&#x0161;i&#x0107;nu snagu. Uz ostale medicinske intervencije kinezioterapija, odnosno provo&#x0111;enje stru&#x010D;no vo&#x0111;enih i pravilno usmjerenih medicinskih vje&#x017E;bi, u &#x0161;irem smislu je pokazatelj uspje&#x0161;nog povratka na posao. Onkolo&#x0161;ki bolesnici &#x017E;ele biti integrirani u normalan &#x017E;ivot i ovakvi odbori imaju za cilj to omogu&#x0107;iti kroz uspostavljanje jedne &#x010D;vrste baze za daljnje aktivne potporne i rehabilitacijske strategije.</p>
</sec>
<sec sec-type="other4">
<title>Naj&#x010D;e&#x0161;&#x0107;i nepovoljni u&#x010D;inci maligne bolesti i lije&#x010D;enja</title>
<p>Osim umora &#x010D;esti nepovoljni u&#x010D;inci maligne bolesti ili posljedice onkolo&#x0161;kog lije&#x010D;enja jesu osteosarkopenija, kemoterapijom inducirana polineuropatija, karcinomska i/ili muskuloskeletna bol, nutritivni deficit, nekroza ili ulceracije zbog ekstravazacije antineoplasti&#x010D;nih lijekova, smanjenje mi&#x0161;i&#x0107;ne snage, smanjenje izdr&#x017E;ljivosti, palmoplantarna eritrodizestezija, sekundarni limfedem, inkontinencija, mukozitis, anksioznost, depresija, kognitivni deficit, dispneja, kaheksija, dobitak na tjelesnoj masi, razli&#x010D;iti motori&#x010D;ki poreme&#x0107;aji, senzomotorni deficit, rizik od padova i posljedi&#x010D;nih fraktura. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>)</p>
</sec>
<sec sec-type="other5">
<title>Prehabilitacija</title>
<p>Prehabilitacija u onkolo&#x0161;koj rehabilitaciji zauzima va&#x017E;no mjesto predstavljaju&#x0107;i sustavni proces u razdoblju od postavljanja dijagnoze do postterapijskog oporavka. Cilj prehabilitacije je izme&#x0111;u ostaloga osposobiti bolesnika da se bolje nosi s tjelesnim i psiholo&#x0161;kim izazovima koje donosi nadolaze&#x0107;e onkolo&#x0161;ko lije&#x010D;enje, bilo kirur&#x0161;ko ili nekirur&#x0161;ko. Prehabilitacija treba biti individualizirana, temeljena na nekoliko &#x010D;imbenika: s obzirom na osnovnu funkcionalnu onesposobljenost bolesnika, vrstu lije&#x010D;enja kojemu &#x0107;e se bolesnik podvrgnuti i ponajvi&#x0161;e s obzirom na tip tjelesnih funkcionalnih deficita koji se kod onkolo&#x0161;kog bolesnika o&#x010D;ekuju. Ako se o&#x010D;ekuje da &#x0107;e imati pote&#x0161;ko&#x0107;e mi&#x0161;i&#x0107;no-ko&#x0161;tanog sustava u smislu ograni&#x010D;enja snage i izdr&#x017E;ljivosti, pote&#x0161;ko&#x0107;e s ravnote&#x017E;om i koordinacijom ili neadekvatnu kinematiku hoda, tada prehabilitacija treba biti stru&#x010D;no vo&#x0111;ena i pravilno usmjerena prema prevladavanju tih potencijalnih deficita u nadolaze&#x0107;em razdoblju. Na&#x010D;elno, &#x0161;to su bolje bolesnici funkcionalno osposobljeni uo&#x010D;i kirur&#x0161;kog i/ili onkolo&#x0161;kog lije&#x010D;enja, sugerira se da &#x0107;e takvima i ostati u tijeku i nakon zavr&#x0161;etka lije&#x010D;enja. Onkolo&#x0161;ka prehabilitacija u&#x010D;inkovita je u smanjenju postoperativnog stresa pobolj&#x0161;avaju&#x0107;i klini&#x010D;ke ishode, smanjuju&#x0107;i stopu komplikacija, optimiziraju&#x0107;i sr&#x010D;ani minutni volumen uo&#x010D;i kirur&#x0161;kog lije&#x010D;enja te skra&#x0107;uju&#x0107;i broj dana provedenih u bolni&#x010D;koj ustanovi. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>&#x2013;<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>)</p>
</sec>
<sec sec-type="other6">
<title>Prednosti kinezioterapije u onkolo&#x0161;koj rehabilitaciji</title>
<p>Za neke vrste malignih bolesti tjelovje&#x017E;ba djeluje preventivno te povisuje op&#x0107;u stopu pre&#x017E;ivljenja. Nedavne smjernice Ameri&#x010D;kog dru&#x0161;tva za sportsku medicinu (engl. <italic>American Society of Sports Medicine,</italic> ASSM) govore u prilog da je tjelovje&#x017E;ba prikladna za onkolo&#x0161;ke bolesnike bez obzira na stadij bolesti. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Stadij maligne bolesti ne mora biti podudaran s op&#x0107;im stanjem bolesnika. Zahvaljuju&#x0107;i otpu&#x0161;tanju endorfina za vrijeme tjelovje&#x017E;be, &#x010D;ak i umjerena tjelesna aktivnost kao &#x0161;etnja poma&#x017E;e u borbi s depresijom i anksiozno&#x0161;&#x0107;u. Metaanaliza na 3.257 onkolo&#x0161;kih bolesnika pokazala je kako umjerena aerobna tjelesna aktivnost sa 70 &#x2013; 80% maksimalnog pulsa ne samo da je izvediva i sigurna, ve&#x0107; je prikazala povoljne u&#x010D;inke na kvalitetu &#x017E;ivota i op&#x0107;e tjelesno funkcioniranje te se odr&#x017E;ala tijekom konkomitantne kemoterapije. (<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>) Neobi&#x010D;no je va&#x017E;na modifikacija navika u smislu zdrave prehrane, prestanka pu&#x0161;enja i konzumacije alkohola te neizostavna psiholo&#x0161;ka potpora uz provo&#x0111;enje tjelesne aktivnosti (aerobne vje&#x017E;be, vje&#x017E;be sna&#x017E;enja i vje&#x017E;be protiv otpora samostalno ili kombinirano). Sve je vi&#x0161;e znanstvenih publikacija koje daju prednost treningu visokog intenziteta nasuprot ustaljenim kontinuiranim vje&#x017E;bama umjerenog intenziteta. Nekoliko autora pokazalo je da je vrijeme provedeno u zoni maksimalnoga aerobnog napora, pove&#x0107;avaju&#x0107;i maksimalni aerobni kapacitet, superiorno u odnosu na umjerene vje&#x017E;be ili bez vje&#x017E;bi. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r21"><italic>21</italic></xref>&#x2013;<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>) Do prije dvadesetak godina zagovaralo se kako se bolesnice oboljele od raka dojke svakako moraju suzdr&#x017E;ati od intenzivnog i u&#x010D;estalog vje&#x017E;banja, kao i izbjegavati vje&#x017E;be koje uklju&#x010D;uju vi&#x0161;estruka ponavljanja. (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>) Sekundarni limfedem je jedna od kroni&#x010D;nih do&#x017E;ivotnih komplikacija nakon kirur&#x0161;kog i radioterapijskog lije&#x010D;enja karcinoma dojke. U radovima koji su provodili istra&#x017E;ivanje na bolesnicama koje su provodile vje&#x017E;be uz otpor umjerenog ili visokog intenziteta nije bilo ne&#x017E;eljenih reakcija u pogledu razvoja sekundarnog limfedema. Za podrobnije poznavanje njihovog u&#x010D;inka potrebna su dodatna istra&#x017E;ivanja. Vje&#x017E;be sna&#x017E;enja tako&#x0111;er nemaju negativan utjecaj na status limfedema i ne pove&#x0107;avaju rizik razvoja limfedema kod bolesnica nakon operacije karcinoma dojke. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r24"><italic>24</italic></xref>) U metaanalizi iz 2017. godine iznesen je zna&#x010D;ajan preokret u smislu kako vje&#x017E;be protiv otpora nemaju &#x0161;tetan u&#x010D;inak na razvoj sekundarnog limfedema povezanog s karcinomom dojke, ve&#x0107; naprotiv imaju povoljan u&#x010D;inak na smanjenje volumena gornjeg ekstremiteta. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>)</p>
</sec>
<sec sec-type="other7">
<title>Specifi&#x010D;nosti kinezioterapije s obzirom na sijelo maligne bolesti</title>
<p>Postoje posebne preporuke glede op&#x0107;enite tjelesne aktivnosti za bolesnike s obzirom na specifi&#x010D;no sijelo maligne bolesti. Zasebno treba stratificirati i evaluirati onkolo&#x0161;ke bolesnike na one s komorbiditetima i bez komorbiditeta. Primjerice, kod skeletnih metastaza potrebno je izbjegavati ve&#x0107;a optere&#x0107;enja trupa kao &#x0161;to su hiperfleksija ili hiperekstenzija trupa, izbjegavati fleksiju ili ekstenziju trupa s dodatnim otporom, izbjegavati torzijske pokrete kralje&#x017E;nice. Neobi&#x010D;no je va&#x017E;no modificirati program vje&#x017E;bi na mjestu ko&#x0161;tane lezije (primarne ili sekundarne), poduzeti mjere za prevenciju padova s obzirom na rizik od posljedi&#x010D;ne frakture te obratiti pozornost na bol u kostima kao znak metastatskog procesa i te bolesnike svakako usmjeriti na klini&#x010D;ku evaluaciju prije nastavka vje&#x017E;bi. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>&#x2013;<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>) Me&#x0111;unarodna radna skupina za provo&#x0111;enje vje&#x017E;be kod bolesnika s metastazama u kostima (engl. <italic>The International Bone Metastases Exercise Working Group,</italic> IBMEWG) osnovana je na temelju spoznaje da bi bolesnici s metastazama u kostima potencijalno mogli imati koristi od vje&#x017E;bi, a &#x010D;esto su ih li&#x0161;eni, budu&#x0107;i da su zdravstveni djelatnici nerijetko suzdr&#x017E;ani u pogledu njihovog indiciranja uslijed nedostatka smjernica u literaturi ili nedovoljnog iskustva u klini&#x010D;koj praksi. Stoga je potrebna identifikacija bolesnika koji su potencijalno izlo&#x017E;eni ve&#x0107;em riziku od skeletnih komplikacija povezanih s vje&#x017E;banjem. Radi se o slo&#x017E;enoj interakciji vi&#x0161;e &#x010D;imbenika koji su povezani s lezijom, primarnom malignom bole&#x0161;&#x0107;u i njezinim lije&#x010D;enjem, kao i samim bolesnikom. (<xref ref-type="bibr" rid="r29"><italic>29</italic></xref>) Kod starijih bolesnika s neuropatijom, kognitivnim deficitom, osteosarkopenijom i mi&#x0161;i&#x0107;nom slabo&#x0161;&#x0107;u onkolo&#x0161;ko lije&#x010D;enje mo&#x017E;e pogor&#x0161;ati sve postoje&#x0107;e tegobe. Nema dovoljno dokaza da no&#x0161;enje kompresivnog rukava za vrijeme tjelovje&#x017E;be smanjuje simptome limfedema povezanog s karcinomom dojke. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Bolesnici opskrbljeni stomom trebaju isprazniti stomu prije provo&#x0111;enja vje&#x017E;bi. Dizanje utega i vje&#x017E;be uz otpor trebaju zapo&#x010D;eti s niskim i doziranim optere&#x0107;enjima. Kod njih je prisutan rizik od razvoja parastomalne hernije. Potrebno je regulirati intraabdominalni tlak modificiraju&#x0107;i vje&#x017E;be koje uzrokuju pove&#x0107;anje intraabdominalnog tlaka, korigirati tehnike podizanja predmeta uzimaju&#x0107;i u obzir izlo&#x017E;enost suprafiziolo&#x0161;kim optere&#x0107;enjima. Kod bolesnika s ileostomom postoji i rizik od dehidracije tijekom vje&#x017E;bi. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>) Kod bolesnika koji uz onkolo&#x0161;ku bolest imaju i perifernu neuropatiju propisuju se vje&#x017E;be ravnote&#x017E;e, hidroterapija, alternativne aerobne vje&#x017E;be poput stacionarnog bicikla i vje&#x017E;be na pokretnoj traci s ru&#x010D;kama. Potrebno je opaziti bilo kakvu nelagodu u rukama kada se primjenjuju slobodni ru&#x010D;ni utezi, voditi ra&#x010D;una o primjeni rukavica odgovaraju&#x0107;eg materijala i teksture tijekom vje&#x017E;banja; dati prednosti vje&#x017E;bama na spravama umjesto slobodnih utega zbog promjene senzibiliteta. (<xref ref-type="bibr" rid="r32"><italic>32</italic></xref>) Temeljno ograni&#x010D;enje za standardiziranu implementaciju vje&#x017E;bi u kontinuum onkolo&#x0161;ke skrbi jest nedostatak literature temeljene na dokazima o pristupu u okviru onkolo&#x0161;ke rehabilitacije, od samog probira bolesnika, evaluacije bazi&#x010D;nog funkcionalnog kapaciteta, propisivanja stru&#x010D;no koordiniranih i pravilno usmjerenih vje&#x017E;bi do pouzdanog pra&#x0107;enja komplikacija tijekom ili izme&#x0111;u provo&#x0111;enja vje&#x017E;bi, primjerice onesposobljenosti u vidu intolerancije napora ili prisutnosti bolne komponente. Tako&#x0111;er, nedostatni su literaturni navodi o bolesnicima koji su skloni pove&#x0107;anom riziku od prijeloma tijekom vje&#x017E;banja, primjerice stariji bolesnici s multiplim mijelomom. (<xref ref-type="bibr" rid="r29"><italic>29</italic></xref>)</p>
</sec>
<sec sec-type="other8">
<title>Princip FITT u kinezioterapiji onkolo&#x0161;kih bolesnika</title>
<p>Rehabilitacijska intervencija u okviru kinezioterapije prema principu FITT (engl. <italic>frequency, intensity, time and type</italic>), s definiranom frekvencijom, intenzitetom, vremenom i tipom vje&#x017E;bi, predstavlja okvir unutar kojega se individualno propisuju medicinske vje&#x017E;be. Pod nadzorom zdravstvenih stru&#x010D;njaka koji se specifi&#x010D;no bave tjelesnom aktivno&#x0161;&#x0107;u osoba s malignom bole&#x0161;&#x0107;u propisuju se vje&#x017E;be prema smjernicama FITT. Prema Campbell i suradnicima definirani su zdravstveni ishodi (anksioznost, depresija, umor, kvaliteta &#x017E;ivota povezana sa zdravljem, tjelesno funkcioniranje, limfedem) povezani s malignom bole&#x0161;&#x0107;u kod kojih postoji dovoljna razina dokaza za propisivanje prema principu FITT (<xref ref-type="table" rid="t1">Table 1 and 2</xref><xref ref-type="table" rid="t2"></xref>). (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Pod pojmom <italic>aerobna aktivnost</italic> smatra se hodanje, vo&#x017E;nja stacionarnog bicikla i drugi oblici aerobne aktivnosti, a vje&#x017E;be uz otpor uklju&#x010D;uju sprave ili slobodne utege. Duljina trajanja programa za gotovo sve ishode je do dvanaest tjedana, a u&#x010D;estalost provo&#x0111;enja dva do tri puta tjedno, s varijabilnim vremenskim trajanjem ili brojem ponavljanja odre&#x0111;enih vje&#x017E;bi. Kod anksioznosti i depresivnih simptoma zabilje&#x017E;ena je u&#x010D;inkovitost aerobne aktivnosti, same ili u kombinaciji s vje&#x017E;bama uz otpor, dok za same vje&#x017E;be uz otpor u&#x010D;inkovitost nije dokazana. Aerobna aktivnost je bila u&#x010D;inkovitija kada se provodila uz nadzor, a umjerena do intenzivnija bila je u&#x010D;inkovitija nego lagana do umjerena. Za umor kod onkolo&#x0161;kih bolesnika opisana je u&#x010D;inkovitost aerobne aktivnosti, vje&#x017E;bi uz otpor i kombinacije (<xref ref-type="table" rid="t1">Table 1</xref>). Kod limfedema povezanog s karcinomom dojke aerobne vje&#x017E;be su se pokazale kao generalno sigurne (u randomiziranim kontroliranim studijama nisu zabilje&#x017E;ene nepo&#x017E;eljne reakcije). Kod provo&#x0111;enja vje&#x017E;bi s otporom program mora zapo&#x010D;eti edukacijom i vje&#x017E;bama s malim otporom koji se postupno pove&#x0107;ava (<xref ref-type="table" rid="t2">Table 2</xref>). (<xref ref-type="bibr" rid="r33"><italic>33</italic></xref>) Me&#x0111;utim, razvoj i domet ovih smjernica ima svoja bitna ograni&#x010D;enja koja treba imati na umu pri radu sa svakim pojedincem. Ve&#x0107;ina dostupne literature jo&#x0161; uvijek izvje&#x0161;tava o najreprezentativnijim tipovima malignih bolesti, primjerice ranom stadiju raka prostate i raka dojke, &#x0161;to ograni&#x010D;ava mogu&#x0107;nosti primjene na druge vrste malignih bolesti ili &#x010D;ak uznapredovale maligne bolesti. I dalje je mogu&#x0107;e da odre&#x0111;eni udio onkolo&#x0161;kih bolesnika mo&#x017E;da ne&#x0107;e mo&#x0107;i tolerirati rehabilitaciju prema principu FITT, koji je utemeljen na dokazima, budu&#x0107;i da je ograni&#x010D;eno eksplicitno dokumentiranje o prilagodbi vje&#x017E;banja u smislu regulacije doze prema toleranciji bolesnika. Stoga bi fizioterapeut ili drugi zdravstveni djelatnik koji nadzire provo&#x0111;enje kinezioterapije trebao pratiti rane znakove intolerancije napora (zaduha, omaglica, bolovi, vrtoglavica) i prilagoditi opseg i sadr&#x017E;aj vje&#x017E;banja u skladu s tim, &#x010D;ak i ako to zna&#x010D;i pad ispod preporu&#x010D;enog opsega vje&#x017E;banja. Nadalje, razumijevanje specifi&#x010D;ne u&#x010D;inkovitosti vje&#x017E;banja za odre&#x0111;eni ishod lije&#x010D;enja ote&#x017E;ano je &#x010D;injenicom da ve&#x0107;ina dosada&#x0161;njih istra&#x017E;ivanja ne uzima u obzir prisutnost i kumuliranje umora uslijed provo&#x0111;enja vje&#x017E;bi te samih po&#x010D;etnih vrijednosti glede funkcionalnih tjelesnih sposobnosti onkolo&#x0161;kog bolesnika kao potencijalnih moderiraju&#x0107;ih &#x010D;imbenika za njihovo provo&#x0111;enje. (<xref ref-type="bibr" rid="r34"><italic>34</italic></xref>, <xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Poznato je da postoje razlike me&#x0111;u onkolo&#x0161;kim bolesnicima s obzirom na demografske karakteristike, sijelo, patohistolo&#x0161;ki nalaz, prognozu, onkolo&#x0161;ko lije&#x010D;enje i nuspojave. Nadalje, postoji vrlo malo znanstveno utemeljenih &#x010D;injenica o prednostima, sigurnosti ili izvedivosti vje&#x017E;banja kod bolesnika koji &#x017E;ive s uznapredovalom malignom bolesti. Potrebna su daljnja istra&#x017E;ivanja kojima bi se unaprijedila razina specifi&#x010D;nosti vje&#x017E;bi za onkolo&#x0161;ke bolesnike kako bi slu&#x017E;ila &#x0161;irem rasponu tipova i stadija malignih bolesti. (<xref ref-type="bibr" rid="r34"><italic>34</italic></xref>)</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Cancer-related health outcome with sufficient evidence for development of fitt prescription according to Campbell et al., 2019 (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="8.9%"/>
<col width="10.65%"/>
<col width="15.09%"/>
<col width="11.53%"/>
<col width="10.06%"/>
<col width="7.98%"/>
<col width="13.01%"/>
<col width="11.54%"/>
<col width="11.24%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Ishod<break/>/outcome</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Tip/Type</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Intenzitet<break/>/Intensity</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Trajanje/(min) ili setovi (ponavljanja)<break/>/Duration (min) or sets (reps)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Tjedna u&#x010D;estalost<break/>/Frequency (sessions per week)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Duljina (tjedni)<break/>/ Length (weeks)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Pod nadzorom samostalno kombinacija<break/>/Setting (supervised, home based or combination)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Doza odgovor<break/>/Dose response</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">Dokazano primarno za ove vrste malignih bolesti<break/>/Evidence primarily from these cancer types</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="4" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Umor<break/>/Fatigue</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Aerobno<break/>/Aerobic</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">65% maksimalnog pulsa/HRmax (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>)<break/>45% maksimalne potro&#x0161;nje kisika/VO<sub>2</sub>max (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)<break/>stopa percepcije napora/1RPE (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) 12</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">30</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">3</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">12</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Uz nadzor ili bez nadzora podjednako u&#x010D;inkovito<break/>/Supervised and unsupervised appear similarly effective</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Mogu&#x0107;i benefit s pove&#x0107;anjem trajanja i duljine programa<break/>/Possible benefits with longer duration &amp; length of program</td>
<td rowspan="4" valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">Ve&#x0107;ina karcinoma dojke, karcinom prostate, razno<break/>/Breast (majority), prostate, mixed</td>
</tr>
<tr>
<td valign="top" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Otpor<break/>/Resistance</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">60% jednog maksimuma ponavljanja/1 RM (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>)<break/>stopa percepcije napora/RPE (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) 12</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">2 seta/sets<break/>12&#x2013;15 ponavljanja<break/>/reps</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">2</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">12</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Uz nadzor ili bez nadzora podjednako u&#x010D;inkovito<break/>/Supervised and unsupervised appear similarly effective</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Nije opa&#x017E;eno<break/>/None observed</td>
</tr>
<tr>
<td rowspan="2" valign="top" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Aerobno+ otpor<break/>/Aerobic + resistance</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">65% maksimalnog pulsa/HRmax (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>)<break/>45% maksimalne potro&#x0161;nje kisika/VO<sub>2</sub>max (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)<break/>stopa percepcije napora/ RPE (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) 12</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">30</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">3</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">12</td>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Uz nadzor ili bez nadzora podjednako u&#x010D;inkovito<break/>/Supervised and unsupervised appear similarly effective</td>
<td rowspan="2" valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Nije opa&#x017E;eno<break/>/None observed</td>
</tr>
<tr>
<td valign="top" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">60% jednog maksimuma ponavljanja/1 RM (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>)<break/>stopa percepcije napora/ RPE (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) 12</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">2 seta/sets<break/>12&#x2013;15 ponavljanja<break/>/reps</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">2</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">12</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>Popis kratica: (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) HRmax &#x2013; maksimalni puls / maximum heart rate; (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) VO<sub>2</sub>max &#x2013; maksimalna potro&#x0161;nja kisika / maximum oxigen uptake; (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) RPE &#x2013; stopa percepcije napora / rate of perceived exertion; (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) RM &#x2013; maksimum ponavljanja / repetition maximum</p>
</table-wrap-foot></table-wrap>
<table-wrap id="t2" position="float">
<label>Table 2</label><caption><title>Cancer-related health outcome with sufficient evidence for development of fitt prescription according to Campbell et al., 2019 (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="9.5%"/>
<col width="10.65%"/>
<col width="10.64%"/>
<col width="11.83%"/>
<col width="10.06%"/>
<col width="10.05%"/>
<col width="11.83%"/>
<col width="13.02%"/>
<col width="12.42%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Ishod<break/>/Outcome</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Tip/Type</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Intenzitet<break/>/Intensity</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Trajanje/(min) ili setovi (ponavljanja)<break/>/Duration (min) or sets (reps)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Tjedna u&#x010D;estalost<break/>/Frequency (sessions per week)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Duljina (tjedni)<break/>/Length (weeks)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Pod nadzorom samostalno kombinacija<break/>/Setting (supervised, home based or combination)</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Doza odgovor<break/>/Dose response</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Dokazano primarno za ove vrste malignih bolesti<break/>/Evidence primarily from these cancer types</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="3" valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Limfedem<break/>/Lympho-edema</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Aerobno<break/>/Aerobic</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Generalno sigurne, u RCT nisu zabilje&#x017E;ene nepo&#x017E;eljne reakcije<break/>/Generally safe, as no significant increase in number of lymphoedema-related adverse events reported in RCT of aerobic exercise</td>
<td rowspan="3" valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Samo limfedem povezan s karcinomom dojke<break/>/Breast cancer-related lymphoedema only</td>
</tr>
<tr>
<td valign="top" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Otpor<break/>/Resistance</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">60&#x2013;70% jednog maksimuma ponavljanja/ 1 RM (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>)<break/>stopa percepcije napora/RPE (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) 15</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1&#x2013;3 seta/ sets<break/>8&#x2013;15 ponavljanja/reps</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2&#x2013;3</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">52</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Svi programi zapo&#x010D;inju edukacijom/All of interventions reviewed started with supervision to teach the exercises</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Po&#x010D;eti s malim otporom i postupno pove&#x0107;avati<break/>/Start resistance a low weight and progress slowly</td>
</tr>
<tr>
<td valign="top" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Aerobno + otpor<break/>/Aerobic + resistance</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Nije primjenjivo<break/>/Not applicable</td>
<td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Nije primjenjivo<break/>/Not applicable</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>Popis kratica: (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) RM &#x2013; maksimum ponavljanja / repetition maximum; (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) RPE &#x2013; stopa percepcije napora / rate of perceived exertion</p>
</table-wrap-foot></table-wrap>
<p>U idealnom slu&#x010D;aju onkolo&#x0161;ki bolesnici trebali bi dobiti sveobuhvatnu procjenu svih komponenti koje utje&#x010D;u na tjelesno funkcioniranje povezano sa zdravljem (sastav tijela, fleksibilnost, gusto&#x0107;a kostiju, kardiorespiratorni kapacitet, mi&#x0161;i&#x0107;na snaga i izdr&#x017E;ljivost), s nekim specifi&#x010D;nim razmatranjima vezano za malignu bolest, kako bi se mogle propisati individualizirane vje&#x017E;be. Me&#x0111;utim, zahtijevanje sveobuhvatne procjene tjelesnog funkcioniranja, drugim rije&#x010D;ima utvr&#x0111;ivanje spremnosti za po&#x010D;etak vje&#x017E;banja mo&#x017E;e stvoriti nepotrebnu prepreku za po&#x010D;etak same onkolo&#x0161;ke rehabilitacije. Iz tog razloga nisu potrebne nikakve procjene za po&#x010D;etak aerobnog treninga niskog intenziteta (hodanje ili vo&#x017E;nja bicikla), treninga s otporom s postupnim pove&#x0107;anjem ili vje&#x017E;bi istezanja kod ve&#x0107;ine onkolo&#x0161;kih bolesnika. Lije&#x010D;ni&#x010D;ki pregled i dalje mo&#x017E;e biti indiciran kao &#x0161;to je prethodno opisano, ovisno o vrsti tjelovje&#x017E;be koja bi se propisivala i samoj anamnezi, napose respektiraju&#x0107;i kardiovaskularne, nefrolo&#x0161;ke ili metaboli&#x010D;ke komorbiditete. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Tjelovje&#x017E;ba ima dobro utvr&#x0111;ene zdravstvene dobrobiti kod osoba bez prisutnosti maligne bolesti, stoga u klini&#x010D;kim studijama koje ispituju u&#x010D;inak tjelovje&#x017E;be ostaje klju&#x010D;no razmatranje mogu li onkolo&#x0161;ki bolesnici tolerirati intenzitet tjelovje&#x017E;bi za koje se zna ili se pretpostavlja da u&#x010D;inkovito pobolj&#x0161;avaju tjelesno zdravlje ili ne. Osim pobolj&#x0161;anja op&#x0107;eg zdravlja, tjelovje&#x017E;ba ujedno umanjuje posljedice same maligne bolesti ili njezinog lije&#x010D;enja. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r33"><italic>33</italic></xref>) Dosada&#x0161;nja istra&#x017E;ivanja nagla&#x0161;avaju pozitivan potencijal pre&#x017E;ivjelih da odgovore na tjelovje&#x017E;bu pobolj&#x0161;anjem pojedinih komponenti tjelesnog zdravlja, uklju&#x010D;uju&#x0107;i sastav tijela (<xref ref-type="bibr" rid="r36"><italic>36</italic></xref>), izdr&#x017E;ljivost i snagu (<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>) te kardiorespiratorni kapacitet (mjerenjem vr&#x0161;nog aerobnog kapaciteta; VO<sub>2</sub>peak). (<xref ref-type="bibr" rid="r38"><italic>38</italic></xref>) Me&#x0111;utim, odgovor pojedinca na podra&#x017E;aj tjelovje&#x017E;bom mo&#x017E;e varirati zbog izravnih u&#x010D;inaka modaliteta onkolo&#x0161;kog lije&#x010D;enja na fiziolo&#x0161;ke sustave: primjerice umor i anemija kao nuspojave onkolo&#x0161;kog lije&#x010D;enja ili radioterapije mogu smanjiti toleranciju na tjelovje&#x017E;bu ili zbog samih demografskih &#x010D;imbenika kao &#x0161;to je visoka &#x017E;ivotna dob. (<xref ref-type="bibr" rid="r39"><italic>39</italic></xref>) Osim toga, tijekom aktivnog onkolo&#x0161;kog lije&#x010D;enja sposobnost pojedinca da podnese napor tijekom tjelovje&#x017E;be mo&#x017E;e varirati na dnevnoj ili tjednoj razini. Razumijevanje ovih interakcija tema je istra&#x017E;ivanja u onkolo&#x0161;koj rehabilitaciji, osobito s pojavom novih lijekova. Specifi&#x010D;no za kardiorespiratorni kapacitet bolesnika, tijekom provo&#x0111;enja lije&#x010D;enja kemoterapijom prisutno je dobro dokumentirano opadanje kardiorespiratorne funkcije, mjereno 6-minutnim testom hoda ili vr&#x0161;nim aerobnim kapacitetom. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Randomizirana ispitivanja pokazuju da aerobne vje&#x017E;be tijekom adjuvantne kemoterapije doprinose o&#x010D;uvanju ili &#x010D;ak pobolj&#x0161;anju kardiorespiratornog kapaciteta, posebno u onih s niskim inicijalnim vrijednostima (<xref ref-type="bibr" rid="r38"><italic>38</italic></xref>), dok drugi opisuju zna&#x010D;ajnije pobolj&#x0161;anje kod bolesnika s vi&#x0161;im inicijalnim vrijednostima. (<xref ref-type="bibr" rid="r40"><italic>40</italic></xref>) &#x010C;ini se da aerobna tjelovje&#x017E;ba sama po sebi, tijekom adjuvantne kemoterapije, ne stimulira ve&#x0107;u proizvodnju crvenih krvnih stanica (<xref ref-type="bibr" rid="r41"><italic>41</italic></xref>), ve&#x0107; pobolj&#x0161;anje kardiorespiratornog kapaciteta ovisi o centralnim prilagodbama, odnosno volumenu plazme i sr&#x010D;anoj funkciji kao i o perifernim prilagodbama, odnosno pobolj&#x0161;anoj vaskularizaciji i funkcioniranju mitohondrijskih enzima. (<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>) Specifi&#x010D;no za mi&#x0161;i&#x0107;no-ko&#x0161;tanu fleksibilnost, kirur&#x0161;ki zahvat mo&#x017E;e rezultirati privremenim ili trajnijim smanjenjem pokretljivosti zglobova i fleksibilnosti tetiva, mi&#x0161;i&#x0107;a, fascija i ko&#x017E;e. Uvijek treba uzeti u obzir na kojem dijelu tijela je izvr&#x0161;en kirur&#x0161;ki zahvat i ako se identificiraju neadekvatni obrasci kretanja potrebno je prilagoditi vje&#x017E;be kako bi se izbjeglo potencijalno neprikladno optere&#x0107;enje drugih tjelesnih struktura i razmotriti upu&#x0107;ivanje na fizikalnu terapiju u nastojanju da se optimizira izvo&#x0111;enje pokreta. Potrebno je prepoznati visokorizi&#x010D;ne bolesnike <italic>per se</italic> i one uslijed nuspojava onkolo&#x0161;kog lije&#x010D;enja; primjerice, povi&#x0161;en rizik za prijelom i kardiovaskularni rizik prilikom primjene hormonske terapije, neuropatija tijekom primjene odre&#x0111;enih citotoksi&#x010D;nih lijekova, bolest sustava za kretanje kao posljedica onkolo&#x0161;kog lije&#x010D;enja, kardiotoksi&#x010D;nost kao posljedica onkolo&#x0161;kog lije&#x010D;enja (<xref ref-type="bibr" rid="r43"><italic>43</italic></xref>). Slijedom navedenog 2010. godine objavljene su ameri&#x010D;ke smjernice temeljem konsenzusa panela stru&#x010D;njaka vezano za propisivanje kinezioterapije kod onkolo&#x0161;kih bolesnika s osvrtom na prethodnu procjenu op&#x0107;eg stanja bolesnika i testiranje za provo&#x0111;enje kinezioterapije kod naj&#x010D;e&#x0161;&#x0107;ih vrsta raka. Kao zlatni standard za procjenu maksimalnog primitka kisika VO<sub>2max</sub> koristi se ergospirometrija (engl. <italic>Cardiopulmonary Exercise Testing</italic>) s kontinuiranim mjerenjem plinova u krvi tijekom rastu&#x0107;eg optere&#x0107;enja. Za procjenu mobilnosti koristi se 6-minutni i 12-minutni test hoda (engl. <italic>6-min;12-min Walking Test</italic>), testovi za procjenu mi&#x0161;i&#x0107;ne snage mjereni s jednim maksimumom ponavljanja (engl. 1 <italic>Repetition Maximum</italic>), test stiska &#x0161;ake mjereno dinamometrom, test brzine hoda (engl. <italic>Gait Speed Test</italic>), test ustajanja sa stolice (engl. <italic>Chair Stand Test</italic>). Test koji objedinjuje procjenu ustajanja, brzinu hodanja, ravnote&#x017E;u i rizik za pad jest <italic>Timed Up and Go Test</italic>. Za procjenu fizi&#x010D;kih ograni&#x010D;enja koristi se SF-36 (engl. <italic>Short Form-36</italic>), a za procjenu kvalitete &#x017E;ivota u svakodnevnim aktivnostima HRQOL (engl. <italic>Health Related Quality of Life</italic>) kako za onkolo&#x0161;ke tako i za neonkolo&#x0161;ke bolesnike. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) Testovi za procjenu statusa gornjih ekstremiteta i ramenog obru&#x010D;a kod bolesnica s rakom dojke koji imaju dobro istra&#x017E;ena psihometrijska svojstva jesu: <italic>Kwan&#x2019;s Arm Problem Scale</italic> (KAPS), <italic>Disability of Arm, Shoulder and Hand</italic> (DASH), <italic>The Upper Extremity Functional Index (</italic>UEFI), <italic>Functional Assessment of Cancer Therapy</italic> (FACT+4). (<xref ref-type="bibr" rid="r41"><italic>41</italic></xref>, <xref ref-type="bibr" rid="r53"><italic>53</italic></xref>) Bolesnici visokog rizika ne samo da vje&#x017E;baju pod nadzorom fizioterapeuta ili kineziologa sa specifi&#x010D;nom edukacijom, ve&#x0107; se u pripravnosti nalaze i zdravstveni djelatnici koji u slu&#x010D;aju potrebe mogu odmah pru&#x017E;iti hitnu pomo&#x0107;. (<xref ref-type="bibr" rid="r40"><italic>40</italic></xref>) Neuromuskularna elektri&#x010D;na stimulacija (engl. <italic>Neuromuscular Electrical Stimulation,</italic> NMES) propisuje se kao opcija kod bolesnika koji nisu u mogu&#x0107;nosti provoditi aktivne vje&#x017E;be s uznapredovalom malignom bolesti, naj&#x010D;e&#x0161;&#x0107;e kod tumora sredi&#x0161;njeg &#x017E;iv&#x010D;anog sustava, multiplim mijelomom i skeletnim metastazama te kod onih kod kojih postoji rizik epilepti&#x010D;nih napadaja i patolo&#x0161;kih fraktura. Ovakvim pasivnim fizikalnoterapijskim modalitetom prevenira se gubitak mi&#x0161;i&#x0107;ne mase. Postoji i niskofrekventni (&lt; 6Hz) u svrhu aerobnog kondicioniranja i visokofrekventni NMES (&gt;20Hz) u svrhu sna&#x017E;enja muskulature. (<xref ref-type="bibr" rid="r44"><italic>44</italic></xref>) <italic>Biofeedback</italic> asistirane vje&#x017E;be kod bolesnika s multiplim mijelomom i komplikacijama u vidu patolo&#x0161;kih fraktura ima zabilje&#x017E;eni u&#x010D;inak u pogledu sna&#x017E;enja muskulature. (<xref ref-type="bibr" rid="r45"><italic>45</italic></xref>)</p>
</sec>
<sec sec-type="other9">
<title>Uloga terapije udarnim valom u rehabilitaciji onkolo&#x0161;kih bolesnika</title>
<p>Kao odgovor na potrebu za u&#x010D;inkovitim, brzim i neinvazivnim zbrinjavanjem bolesti mi&#x0161;i&#x0107;no-ko&#x0161;tanog sustava zadnjih desetlje&#x0107;a u podru&#x010D;ju fizikalne medicine i rehabilitacije razvile su se nove tehnologije kao &#x0161;to su: terapija izvantjelesnim udarnim valom, laser visokog intenziteta, visokoinduktivna magnetoterapija i ciljana radiofrekevencija, koje su se nametnule kao va&#x017E;ni modaliteti u samostalnoj ili kombiniranoj primjeni. U nastavku &#x0107;emo se usmjeriti na terapiju izvantjelesnim udarnim valom, za koji su klini&#x010D;ke i znanstvene studije pokazale sigurnost, terapijsku u&#x010D;inkovitost i financijsku isplativost. Me&#x0111;utim, njezina mogu&#x0107;nost u klini&#x010D;koj praksi jo&#x0161; uvijek ostaje nedostatno iskori&#x0161;tena, uglavnom zbog nesklonosti zdravstvenih djelatnika za propisivanjem. Ova neinvazivna metoda ima dokazane u&#x010D;inkovite biolo&#x0161;ke u&#x010D;inke na smanjenje boli, cijeljenje tkiva i pobolj&#x0161;anje funkcije stimuliraju&#x0107;i prirodnu sposobnost tkiva za samocijeljenje induciraju&#x0107;i upalni proces. Terapija udarnim valom (TUV) kao fizikalnoterapijski modalitet postoji posljednjih 25 godina. Neki muskuloskeletni entiteti kao &#x0161;to su plantarni fascitis, petni trn, kalcificiraju&#x0107;a tendinopatija ramena, teniski lakat ili tendinopatija Ahilove tetive onemogu&#x0107;uju adekvatnu mobilnost bolesnika uslijed bolova i stoga sprje&#x010D;avaju aktivno sudjelovanje u tjelesnoj aktivnosti. Navedeni su klini&#x010D;ki entiteti u standardnom indikacijskom podru&#x010D;ju za lije&#x010D;enje izvantjelesnim udarnim valom kod neonkolo&#x0161;kih bolesnika. Prije zapo&#x010D;injanja provo&#x0111;enja terapijskih vje&#x017E;bi potrebno je smanjiti ili u potpunosti ukloniti bol kako bi se omogu&#x0107;ilo bolesniku da aktivno sudjeluje. Terapija izvantjelesnim udarnim valom predmetom je interesa u kontekstu onkolo&#x0161;ke rehabilitacije posljednjih nekoliko godina. Od 2016. godine promijenila se tradicionalna paradigma vezano za klini&#x010D;ke indikacije i kontraindikacije za propisivanje lije&#x010D;enja udarnim valom kod onkolo&#x0161;kih bolesnika u okviru klini&#x010D;kih preporuka me&#x0111;unarodnog dru&#x0161;tva za lije&#x010D;enje udarnim valom (engl. <italic>International Society for Medical Shockwave Treatment,</italic> ISMST). Maligna bolest kao osnovna bolest (engl. <italic>underlying disease</italic>) vi&#x0161;e ne predstavlja kontraindikaciju za lije&#x010D;enje fokusiranim udarnim valom. Ako je bolno stanje prisutno u sijelu malignog tumora i/ili metastaze, nadalje u podru&#x010D;ju multiplog mijeloma, limfoma, tada je apsolutno kontraindicirano provoditi lije&#x010D;enje udarnim valom na tom mjestu. Aktivna leukemija i leukemi&#x010D;na faza limfoma tako&#x0111;er su apsolutne kontraindikacije. (<xref ref-type="bibr" rid="r46"><italic>46</italic></xref>) Potrebno je u&#x010D;initi minimalnu razinu standardiziranih dijagnosti&#x010D;kih pretraga. U austrijskim klinikama isklju&#x010D;ivo je lije&#x010D;nik specijalist fizikalne medicine i rehabilitacije s edukacijom u tom podru&#x010D;ju kompetentan provoditi terapiju fokusiranim udarnom valom, a fizioterapeut terapiju radijalnim udarnim valom. Publiciran je slu&#x010D;aj bolesnice, izme&#x0111;u ostalih, s metastatskim karcinomom dojke kod koje je uspje&#x0161;no provedeno lije&#x010D;enje fokusiranim udarnim valom uslijed iscrpljuju&#x0107;ih bolova u peti zbog plantarnog fasciitisa. (<xref ref-type="bibr" rid="r47"><italic>47</italic></xref>) Sumarno, izvantjelesni udarni val kontraindiciran je samo na mjestu malignog tumora. Mnogi lije&#x010D;nici jo&#x0161; uvijek su u uvjerenju da je terapija izvantjelesnim udarnim valom kontraindicirana za lije&#x010D;enje boli muskuloskeletnog podrijetla kod onkolo&#x0161;kih bolesnika. Posljedi&#x010D;no velik broj bolesnika ostaje subtretiran i nedovoljno mobiliziran uslijed perzistiraju&#x0107;ih i frustriraju&#x0107;ih muskuloskeletnih bolova. Plantarni fasciitis pove&#x0107;ava prevalenciju padova. Dio onkolo&#x0161;kih bolesnika ima povi&#x0161;en rizik za niskoenergetske padove. (<xref ref-type="bibr" rid="r48"><italic>48</italic></xref>&#x2013;<xref ref-type="bibr" rid="r50"><italic>50</italic></xref>) Padovi iz razumljivih razloga pogor&#x0161;avaju ishod onkolo&#x0161;kog lije&#x010D;enja. Budu&#x0107;i da zdravstvene djelatnike od davnina u lije&#x010D;enju vodi postulat &#x201E;<italic>primum non nocere</italic>&#x201C;, unato&#x010D; novim dokazima, zbog straha od uzrokovanja potencijalne &#x0161;tete bolesniku &#x010D;e&#x0161;&#x0107;e su skloni odluci ne djelovati. Novo, neistra&#x017E;eno i nepoznato poziva na oprez. Prevelik oprez zbog straha i nedovoljnog poznavanja te neutemeljenih vjerovanja mogao bi dovoditi do propusta u lije&#x010D;enju. Osteoporoza, bolest smanjene ko&#x0161;tane mase i poreme&#x0107;ene mikroarhitekture kosti, za koju bolesnice s rakom dojke imaju pove&#x0107;an rizik, ne smatra se kontraindikacijom za lije&#x010D;enje fokusiranim udarnim valom. Na tragu novijih istra&#x017E;ivanja proizlazi da izvantjelesni udarni val ima pozitivan u&#x010D;inak glede formacije kosti. (<xref ref-type="bibr" rid="r51"><italic>51</italic></xref>, <xref ref-type="bibr" rid="r52"><italic>52</italic></xref>) Terapija izvantjelesnim udarnim valom pokazala se u&#x010D;inkovitom u lije&#x010D;enju drugog stadija limfedema i fibroze ko&#x017E;e koje su se pojavile s progresijom ovog stanja. (<xref ref-type="bibr" rid="r53"><italic>53</italic></xref>) U&#x010D;inci te terapije na sekundarni limfedem potvr&#x0111;eni su smanjenim sadr&#x017E;ajem vode i debljine ko&#x017E;e gornjeg ekstremiteta te time smanjenim volumenom ekstremiteta. Uz mehanizam mehanotransdukcije izvantjelesnim udarnim valom aktivira se faktor rasta vaskularnog endotela (VEGF) i fibroblaste, &#x010D;ime se poti&#x010D;e limfna neovaskularizacija. (<xref ref-type="bibr" rid="r54"><italic>54</italic></xref>) Rezultati studija su pokazali da je izvantjelesni udarni val u&#x010D;inkovit za fibroti&#x010D;ne lezije koje se ne mogu u&#x010D;inkovito lije&#x010D;iti samo manualnom ili aparaturnom dekongestivnom fizikalnom terapijom. Samim time je terapija fokusiranim udarnim valom korisna dodatna opcija za rehabilitaciju kojom se nadopunjuje konvencionalna dekongestivna fizikalna terapija.</p>
</sec>
<sec sec-type="other10">
<title>Zaklju&#x010D;ak</title>
<p>Zaklju&#x010D;no, promijenila se paradigma prema kojoj bi onkolo&#x0161;ki bolesnici trebali &#x201E;izbjegavati tjelesnu aktivnost&#x201C;; naprotiv, trebali bi pribjegavati strukturiranoj tjelesnoj aktivnosti, &#x0161;to ponekada uklju&#x010D;uje i vje&#x017E;be umjerenog do visokog intenziteta. Postoji dovoljno utemeljenih dokaza da bi specifi&#x010D;ni aerobni trening, trening uz otpor te kombinirani trening uz otpor i aerobni trening mogli pridonijeti pobolj&#x0161;anju prosje&#x010D;nih zdravstvenih ishoda povezanih s malignom bole&#x0161;&#x0107;u, uklju&#x010D;uju&#x0107;i kvalitetu &#x017E;ivota povezanu sa zdravljem, simptome depresije, anksioznost, tjelesno funkcioniranje i umor. Razumljivo je da sama maligna bolest i njezino lije&#x010D;enje utje&#x010D;u na toleranciju vje&#x017E;banja kod bolesnika i mogu dodatno ovisiti o sveukupnom zdravlju prije postavljanja dijagnoze i funkcionalnoj sposobnosti. Osim toga, literatura je i dalje nedostatna za detaljnije usmjerene preporuke prema tipu maligne bolesti, vremenu lije&#x010D;enja i/ili vrstama lije&#x010D;enja, dok su se preporuke za medicinske vje&#x017E;be rijetko temeljile na studijama koje su izravno uspore&#x0111;ivale razli&#x010D;ite komponente principa FITT, kao &#x0161;to je me&#x0111;usobna usporedba treninga niskog i visokog intenziteta. Pretra&#x017E;ivanjem literature maligna bolest kao osnovna bolest (engl. <italic>underlying disease</italic>) vi&#x0161;e ne predstavlja kontraindikaciju za lije&#x010D;enje izvantjelesnim udarnim valom za klini&#x010D;ke entitete koji su unutar standardnoga indikacijskog podru&#x010D;ja za takvo lije&#x010D;enje. Zdravstveni djelatnici uklju&#x010D;eni u onkolo&#x0161;ku rehabilitaciju trebali bi biti svjesni i po&#x0161;tovati &#x010D;injenicu da pojedinci s dijagnosticiranom malignom bole&#x0161;&#x0107;u obi&#x010D;no imaju mnogo briga, neizvjesnosti i pitanja, poput o&#x010D;ekivanoga &#x017E;ivotnog vijeka, pitanja obiteljskog i radnog okru&#x017E;enja, koja mogu ograni&#x010D;iti davanje prioriteta tjelesnoj aktivnosti u njihovim &#x017E;ivotima. Stoga, kako medicina temeljena na dokazima bilje&#x017E;i kontinuirani napredak u raznim domenama onkologije i ide u korak s evolucijom lije&#x010D;enja malignih bolesti, kao i klini&#x010D;ka ispitivanja koja se pro&#x0161;iruju kako bi uklju&#x010D;ila razli&#x010D;ite modalitete lije&#x010D;enja, sljede&#x0107;a specifi&#x010D;nija generacija preporuka za vje&#x017E;banje kao jedan od modaliteta lije&#x010D;enja mogla bi usmjeriti onkolo&#x0161;ku rehabilitaciju prema istom cilju kao i precizna onkologija gdje se lije&#x010D;enje uskla&#x0111;uje sa specifi&#x010D;nim obilje&#x017E;jima maligne bolesti kod pojedinca.</p>
</sec>
</body>
<back>
<ack>
<title>ZAHVALA</title>
<p>Zahvaljujemo prof. dr. sc. Simeonu Graziu na intelektualnom doprinosu i potpori za ovaj stru&#x010D;ni &#x010D;lanak.</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<p content-type="fn-title">INFORMACIJE O SUKOBU INTERESA</p>
<p>Autori nisu deklarirali sukob interesa relevantan za ovaj rad.</p>
</fn>
<fn fn-type="financial-disclosure">
<p content-type="fn-title">INFORMACIJA O FINANCIRANJU</p>
<p>Za ovaj &#x010D;lanak nisu primljena financijska sredstva.</p>
</fn>
</fn-group>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bower</surname><given-names>JE</given-names></name></person-group>. <article-title>Management of cancer-related fatigue.</article-title> <source>Clin Adv Hematol Oncol</source>. <year>2006</year>;<volume>4</volume>(<issue>11</issue>):<fpage>828</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17143252</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curigliano</surname><given-names>G</given-names></name><name><surname>Cardinale</surname><given-names>D</given-names></name><name><surname>Dent</surname><given-names>S</given-names></name><name><surname>Criscitiello</surname><given-names>C</given-names></name><name><surname>Aseyev</surname><given-names>O</given-names></name><name><surname>Lenihan</surname><given-names>D</given-names></name><etal/></person-group> <article-title>Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.</article-title> <source>CA Cancer J Clin</source>. <year>2016</year>;<volume>66</volume>(<issue>4</issue>):<fpage>309</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21341</pub-id><pub-id pub-id-type="pmid">26919165</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>JM</given-names></name><name><surname>Nilsen</surname><given-names>TS</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>LW</given-names></name></person-group>. <article-title>Exercise Therapy and Cardiovascular Toxicity in Cancer.</article-title> <source>Circulation</source>. <year>2018</year>;<volume>137</volume>(<issue>11</issue>):<fpage>1176</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.024671</pub-id><pub-id pub-id-type="pmid">29530893</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Mariotto</surname><given-names>AB</given-names></name><name><surname>Kramer</surname><given-names>JL</given-names></name><name><surname>Rowland</surname><given-names>JH</given-names></name><etal/></person-group> <article-title>Cancer treatment and survivorship statistics</article-title>. <source>CA Cancer J Clin</source>. <year>2016</year>;<volume>66</volume>(<issue>4</issue>):<fpage>271</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21349</pub-id><pub-id pub-id-type="pmid">27253694</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>KL</given-names></name><name><surname>Winters-Stone</surname><given-names>KM</given-names></name><name><surname>Wiskemann</surname><given-names>J</given-names></name><name><surname>May</surname><given-names>AM</given-names></name><name><surname>Schwartz</surname><given-names>AL</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><etal/></person-group> <article-title>Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable.</article-title> <source>Med Sci Sports Exerc</source>. <year>2019</year>;<volume>51</volume>(<issue>11</issue>):<fpage>2375</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0000000000002116</pub-id><pub-id pub-id-type="pmid">31626055</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>KH</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Matthews</surname><given-names>C</given-names></name><name><surname>Demark-Wahnefried</surname><given-names>W</given-names></name><name><surname>Galv&#x00E3;o</surname><given-names>DA</given-names></name><name><surname>Pinto</surname><given-names>BM</given-names></name><etal/></person-group> <article-title>American College of Sports Medicine roundtable on exercise guidelines for cancer survivors.</article-title> <source>Med Sci Sports Exerc</source>. <year>2010</year>;<volume>42</volume>(<issue>7</issue>):<fpage>1409</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0b013e3181e0c112</pub-id><pub-id pub-id-type="pmid">20559064</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>JK</given-names></name><name><surname>Baima</surname><given-names>J</given-names></name><name><surname>Mayer</surname><given-names>RS</given-names></name></person-group>. <article-title>Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship.</article-title> <source>CA Cancer J Clin</source>. <year>2013</year>;<volume>63</volume>(<issue>5</issue>):<fpage>295</fpage>&#x2013;<lpage>317</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21186</pub-id><pub-id pub-id-type="pmid">23856764</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffart</surname><given-names>LM</given-names></name><name><surname>Kalter</surname><given-names>J</given-names></name><name><surname>Sweegers</surname><given-names>MG</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><etal/></person-group> <article-title>Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs.</article-title> <source>Cancer Treat Rev</source>. <year>2017</year>;<volume>52</volume>:<fpage>91</fpage>&#x2013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctrv.2016.11.010</pub-id><pub-id pub-id-type="pmid">28006694</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="other">Mustian K, Alfano C, Heckler C, Kleckner AS, Kleckner IR, Leach CR, et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. JAMA Oncol. 2017;1;3(7):961&#x2013;8. doi: <pub-id pub-id-type="doi">10.1001/jamaoncol.2016.6914</pub-id>.<pub-id pub-id-type="doi">10.1001/jamaoncol.2016.6914</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>JK</given-names></name><name><surname>Raj</surname><given-names>VS</given-names></name><name><surname>Fu</surname><given-names>JB</given-names></name><name><surname>Wisotzky</surname><given-names>EM</given-names></name><name><surname>Smith</surname><given-names>SR</given-names></name><name><surname>Kirch</surname><given-names>RA</given-names></name></person-group>. <article-title>Cancer rehabilitation and palliative care: critical components in the delivery of high-quality oncology services.</article-title> <source>Support Care Cancer</source>. <year>2015</year>;<volume>23</volume>(<issue>12</issue>):<fpage>3633</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-015-2916-1</pub-id><pub-id pub-id-type="pmid">26314705</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crevenna</surname><given-names>R</given-names></name><name><surname>Kainberger</surname><given-names>F</given-names></name><name><surname>Wiltschke</surname><given-names>C</given-names></name><name><surname>Marosi</surname><given-names>C</given-names></name><name><surname>Wolzt</surname><given-names>M</given-names></name><name><surname>Cenik</surname><given-names>F</given-names></name><etal/></person-group> <article-title>Cancer rehabilitation: current trends and practices within an Austrian University Hospital Center.</article-title> <source>Disabil Rehabil</source>. <year>2020</year>;<volume>42</volume>(<issue>1</issue>):<fpage>2</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1080/09638288.2018.1514665</pub-id><pub-id pub-id-type="pmid">30328719</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crevenna</surname><given-names>R</given-names></name></person-group>. <article-title>Cancer rehabilitation and palliative care-two important parts of comprehensive cancer care.</article-title> <source>Support Care Cancer</source>. <year>2015</year>;<volume>23</volume>(<issue>12</issue>):<fpage>3407</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-015-2977-1</pub-id><pub-id pub-id-type="pmid">26441078</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanaka</surname><given-names>N</given-names></name><name><surname>Tsukamoto</surname><given-names>S</given-names></name><name><surname>Ishida</surname><given-names>Y</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Sajiki</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Clinical questions on rehabilitation in cancer patients with skeletal metastasis: a content analysis of the multidisciplinary tumor board records.</article-title> <source>Support Care Cancer</source>. <year>2021</year>;<volume>29</volume>(<issue>4</issue>):<fpage>2015</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-020-05696-3</pub-id><pub-id pub-id-type="pmid">32844315</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crevenna</surname><given-names>R</given-names></name><name><surname>Keilani</surname><given-names>M</given-names></name></person-group>. <article-title>Relevance of tumor boards for cancer rehabilitation.</article-title> <source>Support Care Cancer</source>. <year>2020</year>;<volume>28</volume>(<issue>12</issue>):<fpage>5609</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-020-05769-3</pub-id><pub-id pub-id-type="pmid">32929536</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crevenna</surname><given-names>R</given-names></name></person-group>. <article-title>From neuromuscular electrical stimulation and biofeedback-assisted exercise up to triathlon competitions-regular physical activity for cancer patients in Austria.</article-title> <source>Eur Rev Aging Phys Act</source>. <year>2013</year>;<volume>10</volume>(<issue>1</issue>):<fpage>53</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/s11556-012-0110-8</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>KE</given-names></name><name><surname>Forsythe</surname><given-names>LP</given-names></name><name><surname>Reeve</surname><given-names>BB</given-names></name><name><surname>Alfano</surname><given-names>CM</given-names></name><name><surname>Rodriguez</surname><given-names>JL</given-names></name><name><surname>Sabatino</surname><given-names>SA</given-names></name><etal/></person-group> <article-title>Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey.</article-title> <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2012</year>;<volume>21</volume>(<issue>11</issue>):<fpage>2108</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-12-0740</pub-id><pub-id pub-id-type="pmid">23112268</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>JK</given-names></name><name><surname>Baima</surname><given-names>J</given-names></name></person-group>. <article-title>Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes.</article-title> <source>Am J Phys Med Rehabil</source>. <year>2013</year>;<volume>92</volume>(<issue>8</issue>):<fpage>715</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1097/PHM.0b013e31829b4afe</pub-id><pub-id pub-id-type="pmid">23756434</pub-id></mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mijwel</surname><given-names>S</given-names></name><name><surname>Jervaeus</surname><given-names>A</given-names></name><name><surname>Bolam</surname><given-names>KA</given-names></name><name><surname>Norrborn</surname><given-names>J</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Rundqvist</surname><given-names>H</given-names></name><etal/></person-group> <article-title>High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship.</article-title> <source>J Cancer Surviv</source>. <year>2019</year>;<volume>13</volume>(<issue>2</issue>):<fpage>244</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1007/s11764-019-00747-z</pub-id><pub-id pub-id-type="pmid">30912010</pub-id></mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egegaard</surname><given-names>T</given-names></name><name><surname>Rohold</surname><given-names>J</given-names></name><name><surname>Lillelund</surname><given-names>C</given-names></name><name><surname>Persson</surname><given-names>G</given-names></name><name><surname>Quist</surname><given-names>M</given-names></name></person-group>. <article-title>Pre-radiotherapy daily exercise training in non-small cell lung cancer: A feasibility study.</article-title> <source>Rep Pract Oncol Radiother</source>. <year>2019</year>;<volume>24</volume>(<issue>4</issue>):<fpage>375</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.rpor.2019.06.003</pub-id><pub-id pub-id-type="pmid">31289452</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cave</surname><given-names>J</given-names></name><name><surname>Paschalis</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Copson</surname><given-names>E</given-names></name><name><surname>Jack</surname><given-names>S</given-names></name><etal/></person-group> <article-title>A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment.</article-title> <source>Support Care Cancer</source>. <year>2018</year>;<volume>26</volume>(<issue>10</issue>):<fpage>3337</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-018-4295-x</pub-id><pub-id pub-id-type="pmid">29936624</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsen</surname><given-names>T</given-names></name><name><surname>Aamot</surname><given-names>IL</given-names></name><name><surname>Haykowsky</surname><given-names>M</given-names></name><name><surname>Rognmo</surname><given-names>&#x00D8;</given-names></name></person-group>. <article-title>High Intensity Interval Training for Maximizing Health Outcomes.</article-title> <source>Prog Cardiovasc Dis</source>. <year>2017</year>;<volume>60</volume>(<issue>1</issue>):<fpage>67</fpage>&#x2013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.pcad.2017.03.006</pub-id><pub-id pub-id-type="pmid">28385556</pub-id></mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mugele</surname><given-names>H</given-names></name><name><surname>Freitag</surname><given-names>N</given-names></name><name><surname>Wilhelmi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Bloch</surname><given-names>W</given-names></name><etal/></person-group> <article-title>High-intensity interval training in the therapy and aftercare of cancer patients: a systematic review with meta-analysis.</article-title> <source>J Cancer Surviv</source>. <year>2019</year>;<volume>13</volume>(<issue>2</issue>):<fpage>205</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/s11764-019-00743-3</pub-id><pub-id pub-id-type="pmid">30806875</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palma</surname><given-names>S</given-names></name><name><surname>Hasenoehrl</surname><given-names>T</given-names></name><name><surname>Jordakieva</surname><given-names>G</given-names></name><name><surname>Ramazanova</surname><given-names>D</given-names></name><name><surname>Crevenna</surname><given-names>R</given-names></name></person-group>. <article-title>High-intensity interval training in the prehabilitation of cancer patients-a systematic review and meta-analysis.</article-title> <source>Support Care Cancer</source>. <year>2021</year>;<volume>29</volume>(<issue>4</issue>):<fpage>1781</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-020-05834-x</pub-id><pub-id pub-id-type="pmid">33106975</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>SR</given-names></name><name><surname>Niesen-Vertommen</surname><given-names>SL</given-names></name></person-group>. <article-title>Challenging the myth of exercise-induced lymphedema following breast cancer: a series of case reports.</article-title> <source>J Surg Oncol</source>. <year>2000</year>;<volume>74</volume>(<issue>2</issue>):<fpage>95</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/1096-9098(200006)74:2&lt;95::AID-JSO3&gt;3.0.CO;2-Q</pub-id><pub-id pub-id-type="pmid">10914817</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keilani</surname><given-names>M</given-names></name><name><surname>Hasenoehrl</surname><given-names>T</given-names></name><name><surname>Neubauer</surname><given-names>M</given-names></name><name><surname>Crevenna</surname><given-names>R</given-names></name></person-group>. <article-title>Resistance exercise and secondary lymphedema in breast cancer survivors-a systematic review.</article-title> <source>Support Care Cancer.</source> <year>2016</year>;<volume>24</volume>(<issue>4</issue>):<fpage>1907</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-015-3068-z</pub-id><pub-id pub-id-type="pmid">26715294</pub-id></mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galv&#x00E3;o</surname><given-names>DA</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Spry</surname><given-names>N</given-names></name><name><surname>Cormie</surname><given-names>P</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Chambers</surname><given-names>SK</given-names></name><etal/></person-group> <article-title>Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases.</article-title> <source>Med Sci Sports Exerc</source>. <year>2018</year>;<volume>50</volume>(<issue>3</issue>):<fpage>393</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0000000000001454</pub-id><pub-id pub-id-type="pmid">29036016</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rief</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>LC</given-names></name><name><surname>Omlor</surname><given-names>G</given-names></name><name><surname>Akbar</surname><given-names>M</given-names></name><name><surname>Bruckner</surname><given-names>T</given-names></name><name><surname>Rieken</surname><given-names>S</given-names></name><etal/></person-group> <article-title>The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients &#x2013; a randomized trial.</article-title> <source>Radiother Oncol</source>. <year>2014</year>;<volume>112</volume>(<issue>1</issue>):<fpage>133</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.radonc.2014.06.008</pub-id><pub-id pub-id-type="pmid">25012645</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frost</surname><given-names>HM</given-names></name></person-group>. <article-title>Should future risk-of-fracture analyses include another major risk factor? The case for falls.</article-title> <source>J Clin Densitom</source>. <year>2001</year>;<volume>4</volume>(<issue>4</issue>):<fpage>381</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1385/JCD:4:4:381</pub-id><pub-id pub-id-type="pmid">11748343</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>KL</given-names></name><name><surname>Cormie</surname><given-names>P</given-names></name><name><surname>Weller</surname><given-names>S</given-names></name><name><surname>Alibhai</surname><given-names>SM</given-names></name><name><surname>Bolam</surname><given-names>KA</given-names></name><name><surname>Campbell</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Exercise Recommendation for People With Bone Metastases: Expert Consensus for Health Care Providers and Exercise Professionals.</article-title> <source>JCO Oncol Pract</source>. <year>2022</year>;<volume>18</volume>(<issue>5</issue>):<fpage>e697</fpage>&#x2013;<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1200/OP.21.00454</pub-id><pub-id pub-id-type="pmid">34990293</pub-id></mixed-citation></ref>
<ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paskett</surname><given-names>ED</given-names></name><name><surname>Dean</surname><given-names>JA</given-names></name><name><surname>Oliveri</surname><given-names>JM</given-names></name><name><surname>Harrop</surname><given-names>JP</given-names></name></person-group>. <article-title>Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review.</article-title> <source>J Clin Oncol</source>. <year>2012</year>;<volume>30</volume>(<issue>30</issue>):<fpage>3726</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2012.41.8574</pub-id><pub-id pub-id-type="pmid">23008299</pub-id></mixed-citation></ref>
<ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esper</surname><given-names>P</given-names></name></person-group>. <article-title>Symptom clusters in individuals living with advanced cancer.</article-title> <source>Semin Oncol Nurs</source>. <year>2010</year>;<volume>26</volume>(<issue>3</issue>):<fpage>168</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.soncn.2010.05.002</pub-id><pub-id pub-id-type="pmid">20656140</pub-id></mixed-citation></ref>
<ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streckmann</surname><given-names>F</given-names></name><name><surname>Zopf</surname><given-names>EM</given-names></name><name><surname>Lehmann</surname><given-names>HC</given-names></name><name><surname>May</surname><given-names>K</given-names></name><name><surname>Rizza</surname><given-names>J</given-names></name><name><surname>Zimmer</surname><given-names>P</given-names></name><etal/></person-group> <article-title>Exercise intervention studies in patients with peripheral neuropathy: a systematic review.</article-title> <source>Sports Med</source>. <year>2014</year>;<volume>44</volume>(<issue>9</issue>):<fpage>1289</fpage>&#x2013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1007/s40279-014-0207-5</pub-id><pub-id pub-id-type="pmid">24927670</pub-id></mixed-citation></ref>
<ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winters-Stone</surname><given-names>KM</given-names></name><name><surname>Neil</surname><given-names>SE</given-names></name><name><surname>Campbell</surname><given-names>KL</given-names></name></person-group>. <article-title>Attention to principles of exercise training: a review of exercise studies for survivors of cancers other than breast.</article-title> <source>Br J Sports Med</source>. <year>2014</year>;<volume>48</volume>(<issue>12</issue>):<fpage>987</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2012-091732</pub-id><pub-id pub-id-type="pmid">23293010</pub-id></mixed-citation></ref>
<ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Courneya</surname><given-names>KS</given-names></name></person-group>. <article-title>Physical activity and cancer survivorship: a simple framework for a complex field.</article-title> <source>Exerc Sport Sci Rev</source>. <year>2014</year>;<volume>42</volume>(<issue>3</issue>):<fpage>102</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1249/JES.0000000000000011</pub-id><pub-id pub-id-type="pmid">24508735</pub-id></mixed-citation></ref>
<ref id="r35"><label>35</label><mixed-citation publication-type="book">Riebe D, Ehrman JK, Liguor G, Magal M. ACSM&#x2019;s: Guidelines fo Exercise Testing and Prescription. 10. izd. Philadelphia: Wolters Kluwer; 2018.</mixed-citation></ref>
<ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padilha</surname><given-names>CS</given-names></name><name><surname>Marinello</surname><given-names>PC</given-names></name><name><surname>Galv&#x00E3;o</surname><given-names>DA</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><name><surname>Borges</surname><given-names>FH</given-names></name><name><surname>Frajacomo</surname><given-names>F</given-names></name><etal/></person-group> <article-title>Evaluation of resistance training to improve muscular strength and body composition in cancer patients undergoing neoadjuvant and adjuvant therapy: a meta-analysis.</article-title> <source>J Cancer Surviv</source>. <year>2017</year>;<volume>11</volume>:<fpage>339</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1007/s11764-016-0592-x</pub-id><pub-id pub-id-type="pmid">28054255</pub-id></mixed-citation></ref>
<ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>JT</given-names></name><name><surname>Hartland</surname><given-names>MC</given-names></name><name><surname>Maloney</surname><given-names>LT</given-names></name><name><surname>Davison</surname><given-names>K</given-names></name></person-group>. <article-title>Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials.</article-title> <source>Br J Sports Med</source>. <year>2018</year>;<volume>52</volume>(<issue>20</issue>):<fpage>1311</fpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2017-098285</pub-id><pub-id pub-id-type="pmid">29549149</pub-id></mixed-citation></ref>
<ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>JM</given-names></name><name><surname>Zabor</surname><given-names>EC</given-names></name><name><surname>Schwitzer</surname><given-names>E</given-names></name><name><surname>Koelwyn</surname><given-names>GJ</given-names></name><name><surname>Adams</surname><given-names>SC</given-names></name><name><surname>Nilsen</surname><given-names>TS</given-names></name><etal/></person-group> <article-title>Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis.</article-title> <source>J Clin Oncol</source>. <year>2018</year>;<volume>36</volume>(<issue>22</issue>):<fpage>2297</fpage>&#x2013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2017.77.5809</pub-id><pub-id pub-id-type="pmid">29894274</pub-id></mixed-citation></ref>
<ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweegers</surname><given-names>MG</given-names></name><name><surname>Altenburg</surname><given-names>TM</given-names></name><name><surname>Brug</surname><given-names>J</given-names></name><name><surname>May</surname><given-names>AM</given-names></name><name><surname>van Vulpen</surname><given-names>JK</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><etal/></person-group> <article-title>Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data.</article-title> <source>Br J Sports Med</source>. <year>2019</year>;<volume>53</volume>(<issue>13</issue>):<fpage>812</fpage>. <pub-id pub-id-type="doi">10.1136/bjsports-2018-099191</pub-id><pub-id pub-id-type="pmid">30181323</pub-id></mixed-citation></ref>
<ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffart</surname><given-names>LM</given-names></name><name><surname>Steindorf</surname><given-names>K</given-names></name><name><surname>Bohus</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Potthoff</surname><given-names>K</given-names></name><name><surname>Wiskemann</surname><given-names>J</given-names></name></person-group>. <article-title>Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis.</article-title> <source>J Natl Cancer Inst</source>. <year>2018</year>;<volume>110</volume>(<issue>11</issue>):<fpage>1190</fpage>&#x2013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djy161</pub-id><pub-id pub-id-type="pmid">30299508</pub-id></mixed-citation></ref>
<ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolan</surname><given-names>LB</given-names></name><name><surname>Gelmon</surname><given-names>K</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Mackey</surname><given-names>JR</given-names></name><name><surname>Segal</surname><given-names>RJ</given-names></name><name><surname>Lane</surname><given-names>K</given-names></name><etal/></person-group> <article-title>Hemoglobin and aerobic fitness changes with supervised exercise training in breast cancer patients receiving chemotherapy.</article-title> <source>Cancer Epidemiol Biomarkers Prev.</source> <year>2010</year>;<volume>19</volume>(<issue>11</issue>):<fpage>2826</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-10-0521</pub-id><pub-id pub-id-type="pmid">20861399</pub-id></mixed-citation></ref>
<ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakoski</surname><given-names>SG</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>Douglas</surname><given-names>PS</given-names></name><name><surname>Jones</surname><given-names>LW</given-names></name></person-group>. <article-title>Exercise rehabilitation in patients with cancer.</article-title> <source>Nat Rev Clin Oncol</source>. <year>2012</year>;<volume>9</volume>(<issue>5</issue>):<fpage>288</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1038/nrclinonc.2012.27</pub-id><pub-id pub-id-type="pmid">22392097</pub-id></mixed-citation></ref>
<ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>JM</given-names></name><name><surname>Lakoski</surname><given-names>S</given-names></name><name><surname>Mackey</surname><given-names>JR</given-names></name><name><surname>Douglas</surname><given-names>PS</given-names></name><name><surname>Haykowsky</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>LW</given-names></name></person-group>. <article-title>The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.</article-title> <source>Oncologist</source>. <year>2013</year>;<volume>18</volume>(<issue>2</issue>):<fpage>221</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.2012-0226</pub-id><pub-id pub-id-type="pmid">23335619</pub-id></mixed-citation></ref>
<ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x2019;Connor</surname><given-names>D</given-names></name><name><surname>Caulfield</surname><given-names>B</given-names></name></person-group>. <article-title>The application of neuromuscular electrical stimulation (NMES) in cancer rehabilitation: current prescription, pitfalls, and future directions.</article-title> <source>Support Care Cancer</source>. <year>2018</year>;<volume>26</volume>(<issue>11</issue>):<fpage>3661</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-018-4269-z</pub-id><pub-id pub-id-type="pmid">29789948</pub-id></mixed-citation></ref>
<ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keilani</surname><given-names>M</given-names></name><name><surname>Kainberger</surname><given-names>F</given-names></name><name><surname>Pataraia</surname><given-names>A</given-names></name><name><surname>Hasen&#x00F6;hrl</surname><given-names>T</given-names></name><name><surname>Wagner</surname><given-names>B</given-names></name><name><surname>Palma</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Typical aspects in the rehabilitation of cancer patients suffering from metastatic bone disease or multiple myeloma.</article-title> <source>Wien Klin Wochenschr</source>. <year>2019</year>;<volume>131</volume>(<issue>21&#x2013;22</issue>):<fpage>567</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1007/s00508-019-1524-3</pub-id><pub-id pub-id-type="pmid">31267163</pub-id></mixed-citation></ref>
<ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crevenna</surname><given-names>R</given-names></name><name><surname>Mickel</surname><given-names>M</given-names></name><name><surname>Keilani</surname><given-names>M</given-names></name></person-group>. <article-title>Extracorporeal shock wave therapy in the supportive care and rehabilitation of cancer patients.</article-title> <source>Support Care Cancer</source>. <year>2019</year>;<volume>27</volume>(<issue>11</issue>):<fpage>4039</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-019-05046-y</pub-id><pub-id pub-id-type="pmid">31446484</pub-id></mixed-citation></ref>
<ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zdravkovic</surname><given-names>A</given-names></name><name><surname>Mickel</surname><given-names>M</given-names></name><name><surname>Crevenna</surname><given-names>R</given-names></name></person-group>. <article-title>Successful application of focused extracorporeal shockwave therapy for plantar fasciitis in patients suffering from metastatic breast cancer.</article-title> <source>Support Care Cancer</source>. <year>2021</year>;<volume>29</volume>(<issue>8</issue>):<fpage>4187</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1007/s00520-021-06117-9</pub-id><pub-id pub-id-type="pmid">33745042</pub-id></mixed-citation></ref>
<ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menz</surname><given-names>HB</given-names></name><name><surname>Auhl</surname><given-names>M</given-names></name><name><surname>Spink</surname><given-names>MJ</given-names></name></person-group>. <article-title>Foot problems as a risk factor for falls in community-dwelling older people: A systematic review and meta-analysis.</article-title> <source>Maturitas</source>. <year>2018</year>;<volume>118</volume>:<fpage>7</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.maturitas.2018.10.001</pub-id><pub-id pub-id-type="pmid">30415759</pub-id></mixed-citation></ref>
<ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildes</surname><given-names>TM</given-names></name><name><surname>Dua</surname><given-names>P</given-names></name><name><surname>Fowler</surname><given-names>SA</given-names></name><name><surname>Miller</surname><given-names>JP</given-names></name><name><surname>Carpenter</surname><given-names>CR</given-names></name><name><surname>Avidan</surname><given-names>MS</given-names></name><etal/></person-group> <article-title>Systematic review of falls in older adults with cancer.</article-title> <source>J Geriatr Oncol</source>. <year>2015</year>;<volume>6</volume>(<issue>1</issue>):<fpage>70</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgo.2014.10.003</pub-id><pub-id pub-id-type="pmid">25454770</pub-id></mixed-citation></ref>
<ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maltser</surname><given-names>S</given-names></name><name><surname>Cristian</surname><given-names>A</given-names></name><name><surname>Silver</surname><given-names>JK</given-names></name><name><surname>Morris</surname><given-names>GS</given-names></name><name><surname>Stout</surname><given-names>NL</given-names></name></person-group>. <article-title>A Focused Review of Safety Considerations in Cancer Rehabilitation.</article-title> <source>PM R</source>. <year>2017</year>;<volume>9</volume>(<issue>9S2</issue>):<fpage>S415</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.pmrj.2017.08.403</pub-id><pub-id pub-id-type="pmid">28942913</pub-id></mixed-citation></ref>
<ref id="r51"><label>51</label><mixed-citation publication-type="other">Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R,, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;1;37(31):2916&#x2013;46. doi: <pub-id pub-id-type="doi">10.1200/JCO.19.01696</pub-id>.<pub-id pub-id-type="doi">10.1200/JCO.19.01696</pub-id></mixed-citation></ref>
<ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auersperg</surname><given-names>V</given-names></name><name><surname>Trieb</surname><given-names>K</given-names></name></person-group>. <article-title>Extracorporeal shock wave therapy: an update.</article-title> <source>EFORT Open Rev</source>. <year>2020</year>;<volume>5</volume>(<issue>10</issue>):<fpage>584</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1302/2058-5241.5.190067</pub-id><pub-id pub-id-type="pmid">33204500</pub-id></mixed-citation></ref>
<ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Kim</surname><given-names>SB</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group>. <article-title>Effects of Extracorporeal Shockwave Therapy on Improvements in Lymphedema, Quality of Life, and Fibrous Tissue in Breast Cancer-Related Lymphedema.</article-title> <source>Ann Rehabil Med</source>. <year>2020</year>;<volume>44</volume>(<issue>5</issue>):<fpage>386</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.5535/arm.19213</pub-id><pub-id pub-id-type="pmid">32986941</pub-id></mixed-citation></ref>
<ref id="r54"><label>54</label><mixed-citation publication-type="other">Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;15;438(7070):946&#x2013;53. doi: <pub-id pub-id-type="doi">10.1038/nature04480</pub-id>.<pub-id pub-id-type="doi">10.1038/nature04480</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
